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Abstract 
In recent years, it has become apparent that sub-micron scale remnants of cells, called 
microparticles (MPs), are present in human circulation. MPs contain DNA, RNA, protein and 
lipids (such as cholesterol). Increased numbers of MPs are observed in autoimmune conditions 
such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). This work aims to 
address the deficiency in the literature concerning MP cholesterol (MPC) by establishing reference 
values for MPC in a representative healthy population group, and by investigating the potential of 
MP cholesterol as a biomarker in autoimmunity. 
This study has optimised a reproducible and feasible method (centrifugation followed by 
size exclusion chromatography) to isolate apolipoprotein-deficient, cholesterol containing MPs 
from plasma, allowing the study of cholesterol without lipoprotein contamination in a disease 
model. A reference range for MPC was established in a representative healthy population. Studies 
in autoimmune patients suggest that MPC holds potential as a novel biomarker for SLE and RA 
patient diagnosis and stratification. RA patients have significantly more MPC than SLE patients 
and healthy controls. The study also confirmed the potential of 3-hexanoyl-7-nitrobenz-2-oxa-1,3-
diazol-4-yl-cholesterol (3NBDC) as a versatile cholesterol tracer in different cell models and 
extracellular vesicles.  
To the best of our knowledge, this thesis reports the first studies of lipoprotein deficient 
MPs in autoimmune disease. The methods used in this study could be applied to the investigation 
of this MP subset in other diseases. The work involving 3NBDC has shed new light on the multiple 
application of 3NBDC as a cholesterol tracer. In addition, the application of 3NBDC contributes 
to a better understanding of the dynamics of cholesterol and extracellular vesicles. 
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1.1 Extracellular Vesicles  
The first study of extracellular vesicles (EVs) as procoagulant platelet-derived particles in normal 
plasma was described by Chargaff and West in 1946. In 1967, Peter Wolf referred to EVs as 
“platelet dust” to describe this subcellular coagulant material (1, 2). Over the past few decades,      
accumulating data,  indicates that EVs are a heterogeneous group based on their contents, size and 
cellular source. At present, EVs are generally classified into three main types that exist in 
circulation: microparticles (MPs)/microvesicles, exosomes and apoptotic bodies (Figure 1.1). 
Exosomes are derived from endosomal compartments within the cell, with their size ranging from 
0.04-0.1µm. Apoptotic bodies are derived from cells undergoing apoptotic processes and contain 
remnants of apoptotic cells including cytoplasm, organelles and nuclear contents (3). Their size is 
around 0.8-5µm, making them much larger than exosomes and MPs (4, 5). MPs are small vesicles 
(with a diameter of 0.1-1µm) derived from almost all cell types in response to activation, apoptosis 
and injury (4, 5). There are some key differences between these three subtypes of EVs, specifically 
in their physical characteristics and the methods used to isolate and detect them (Table 1.1).  
          The main focus of this study is around the characterisation and role of plasma derived MPs. 
MPs, present in the circulation, are predominately derived from platelets, erythrocytes, leucocytes 
and endothelial cells (6, 7). Many different antigens may be used to detect their cellular origin, 
usually by flow cytometry. In recent years it has been shown that MPs are involved in 
pathophysiological processes in autoimmune disease, cardiovascular disease (CVD) and many 
other diseases (8). The exact details around MP biogenesis, secretion and their fate in different 
diseases still remains to be elucidated. 
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Figure 1.1 Different types of extracellular vesicles. Exosomes are secreted from endosomes. 
Microvesicles (microparticles) are derived from cell membranes by budding and shedding 
processes. Apoptotic bodies are formed in the late phase of apoptosis when the cell's cytoskeleton 
breaks down and causes the membrane to bulge outward. Extracellular vesicles express numerous 
markers such as MHC, cell specific receptors, lipids and nucleic acids (9). 
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Table1.1: Comparison of the Common Characteristics of Exosomes, Microparticles and 
Apoptotic Bodies 
Characteristics Exosomes Microparticles Apoptotic bodies 
Size (diameter) 
 
0.04-0.1µm 0.1-1µm 0.8-5µm 
Origin Multivesicular bodies 
(endosomes/ 
lysosomes) 
 
Different cells 
membrane 
 
Different apoptotic 
cells 
Mechanism of 
release 
Cell activation Cell apoptosis, 
activation or injury 
Late phase of 
apoptosis 
 
Composition Protein, nucleic acid, 
lipid 
Protein, nucleic acid, 
lipid 
Cytoplasm, 
organelles, 
Nuclear contents 
 
Centrifugation 
force 
100,000 - 200,000g ~20,000g 10,000 - 16,000g 
Isolation 
methods 
1. Differential ultra-
centrifugation 
2. Density gradient 
ultra-centrifugation 
3. Size-exclusion 
chromatography 
4. Kit based 
precipitation 
 
1. Differential ultra-
centrifugation 
2. Density gradient 
ultra-centrifugation 
3. Size-exclusion 
chromatography 
4. Kit based 
precipitation 
 
1. Differential 
centrifugation 
Methods for 
detection 
1. Electron 
microscopy 
2. Flow cytometry 
3. Dynamic light 
scattering 
4. Tunable resistive 
pulse sensing 
5. Nanoparticle 
tracking analysis 
 
1. Electron 
microscopy 
2. Flow cytometry 
3. Dynamic light 
scattering 
4. Tunable resistive 
pulse sensing 
5. Nanoparticle 
tracking analysis 
 
1. Flow cytometry 
Markers used to 
detect the 
particles 
 
CD63, CD9,CD81 Variable, depends on 
cell of origin 
(see Table 1.2) 
Annexin-V 
References 
 
(4) (5) (10) (10) (11) (5) (12) 
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1.2 Microparticles 
All cell types appear to be able produce MPs in response to stimuli and are typically detected by 
flow cytometry utilising the expression of different cell surface markers (Table 1.2). MPs are 
present in biological fluids such as plasma and are involved in various physiological and 
pathological processes (1). They are composed of protein, nucleic acid and lipid (7).  
 
 Table 1.2: Common Antigens Used to Identify Microparticle Cellular Origin 
 
Microparticle Cell 
of Origin 
Antigen References 
Erythrocyte  CD235a (13) 
Platelet CD41, CD42a, CD42b, CD61,CD62P 
CD31+/CD42+, CD63 
(14) (15) 
Endothelial cell CD31+/CD42, CD146, CD106, CD51, CD144, CD62E, 
CD105, CD54 
(14) (15) 
Leucocyte CD45 (13) 
Granulocyte CD66b (13) 
Monocyte CD14 (13) 
Lymphocyte CD4, CD8, CD20,CD3 (13) (14) (16) 
 
1.2.1 Structure of microparticles 
Lipid content and membrane features 
Under resting conditions, phospholipids are asymmetrically distributed in the inner and outer 
leaflets of the plasma membrane, with phosphatidylcholine (PC) and sphingomyelin (SM) 
enriched in the outer leaflets and phosphatidylserine (PS) and phosphatidylethanolamine (PE) 
enriched in the inner leaflets (17). It is generally accepted that when a cell membrane loses the 
asymmetrical distribution of these lipids, this results in the release of MPs (18). During apoptosis 
or cellular activation, the cytoskeleton is reorganised, leading to PS exposure on the outer cell 
membrane and shedding of MPs (18). PS externalisation is a widely accepted hallmark of MPs. 
This PS may be detected via a variety of PS-specific proteins coupled to fluorophores such as  
annexin-V and lactadherin, which are the most commonly used probes (19). Annexin-V binds to 
PS to identify apoptotic cells in the presence of calcium, while lactadherin is also a PS binding 
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protein, but independent of calcium (20). However, several studies have shown that PS-negative 
MPs also exist in circulation (21, 22, 23). Furthermore, a number of studies have detected that MPs 
contain three other phospholipids, PC, SM and PE (24, 25, 26). Nieuwland et al report that MPs 
contain 59% PC, 20.6% SM and 9.4% PE (27). A lipidomic study further reported that MPs contain 
other lipid species, such as phosphatidylinositol, phosphatidic acid and phosphatidylglycerol (28). 
Biró et al demonstrated that platelet-derived MPs also contain cholesterol and phospholipids (29). 
However, it should be noted that most of these studies have in fact analysed the lipidomes of 
exosomes rather than MPs (30, 31). There is, therefore, a lack of information around the lipid 
content of MPs within the field, with further studies being needed to elucidate both the lipid 
composition and biological function of these particles.   
Protein Composition 
Proteins are critical bioactive contents of MP, with proteomic methods commonly used approach 
to study MP-derived protein. Multiple studies have identified different proteins present in plasma 
MPs, with the overall MP proteome influenced by different isolation strategies and biological 
sources (32, 33). Recently, Tamar et al have identified 5374 proteins to be present in plasma MPs 
which is the largest proteome reported so far (34). According to Vesiclepedia (35) there are 100 
proteins regularly identified in EVs. Among these 100 proteins, PDCD61P, GAPDH and HSPA8 
are the most frequently identified in EVs including MPs. 
Nucleic Acid Cargo 
 Numerous studies have reported that MPs contain different nucleic acids including DNA, 
microRNAs (miRs) and messenger RNA (mRNA) (36, 37, 38). During cell death, either apoptosis 
or necrosis, DNA can exit the cell and enter into the extracellular space (39). Pisetsky et al have 
reported that MPs are a source of extracellular DNA (39). It is also generally accepted that MPs 
act as transport vesicles for miRs (38) and MPs  may act as protective transport vesicles for miRs 
in the circulation (38). This activity is attributed to exclusion of circulating RNases from the MP 
cargo.  Several studies have demonstrated that MPs can transport mRNA or miRs to recipient cells 
 11 
(40, 41), and can transfer this mRNA or miRNA into recipient cells (such as macrophages, 
leucocytes and endothelial cells) by internalisation to regulate cell function and gene expression 
(42). 
1.2.2 Biological activities of microparticle content and disease association  
The biological activities of MPs are closely related to their contents. Phospholipids are known play 
a key role in the pro-coagulant process (43,44,45). Wolberg et al have reported that PS+ positive 
MPs contribute to the formation of coagulation complexes and increase tissue factor activity (46). 
One study further suggested that PS+ positive MPs are more pro-coagulant than PS-negative MPs, 
due to PS binding coagulation proteins called “vitamin K-dependent carboxylation/g-
carboxyglutamic acid-rich (GLA)” domains (47), which are involved in coagulation. These PS 
exposed MPs are associated with thrombotic diseases (47).  
         Some studies have analysed the proteome of MPs and discovered MPs derived protein as 
biomarkers in different diseases (48, 49). For example, in type 2 diabetes, a total of 496 proteins 
have been identified in plasma MPs, with 20 MP proteins having a higher expression in the patient 
group when compared to healthy controls (50). Wattes et al identified a total of 160 proteins in 
plasma MPs in a pulmonary embolism group and healthy control group, with 23 unique proteins 
being found in the pulmonary embolism group alone (51). These studies suggest MP-derived 
proteins may hold promise as novel biomarkers in multiple diseases.  
        Furthermore, various studies have reported that MPs contain different miRs in different 
disease situations. Jansen et al report that the level of miR-126 and miR-26a is significantly 
reduced in diabetes compared to non-diabetes (52). They suggest that endothelial cell MPs are the 
main source of miR-126 and miR-26a and these miRs are related to appropriate vascular 
performance. Endothelial MPs can deliver functional miR-126 which contributes to endothelial 
cell repair. This study also identified ten miRs (miR-126, miR-222, miR-let7d, miR-21, miR-20a, 
miR-27a, miR-92a, miR-17, miR-130, and miR-199a) present in circulating MPs in stable 
coronary artery disease which were related to vascular performance. Endothelial cells and platelets 
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are believed to be the main sources of MPs containing miR-126 and miR-199a (52, 53). A more 
recent study demonstrated that miR-9 and miR-451 were differentially expressed in cerebrospinal 
fluid (CSF), with more MPs being derived from brain injured patients compared to non-injured 
subjects, suggesting MPs containing miR may play a role in the adaptive response to injury (54). 
Additionally, CSF MPs have been shown to contain mRNA (54). Charles et al also reported that 
MPs contain DNA and RNA after studying apoptotic Jurkat and HL-60 cell models (55). Taken 
together, these studies demonstrate that MP contents contribute to MPs acting as a messenger and 
transmitter of biological information. 
1.2.3 Isolation and purification of microparticles 
The options available for isolation and purification of pure MPs are limited. Currently, there are 
four main methods used to isolate MPs derived from body fluids and conditioned media. These 
are differential ultra-centrifugation, density gradient ultracentrifugation, size-exclusion 
chromatography (SEC) and precipitation (Table 1.3). The most commonly used method for MP 
isolation from body fluids or cell culture media is differential centrifugation/ultra-centrifugation. 
This method involves a series of centrifugation steps, which is time-consuming. Another drawback 
to this method is that the isolated MPs potentially contain soluble plasma proteins and lipoproteins 
(56). It is thought that certain purification methods can influence the function of MPs, for example, 
it has been shown EVs isolated by a protein organic solvent precipitation method and treated cells 
resulted in reduced cell viability in vitro (57). Other methods like immunoaffinity isolation 
methods (microbeads coated with certain EV surface markers) can lead to substantial populations 
of EVs being lost due to beads only binding a certain subset of EVs (58). Furthermore, other 
studies suggest that the use of a density gradient ultracentrifugation method may in fact influence 
the biological functions of MPs (59). In general,  it is challenging to directly compare results for 
any MP isolation method used across different laboratories due to the variation in protocols and 
equipment. MPs also share biophysical properties with other small vesicles (such as lipoproteins 
and virions) and these factors can significantly complicate their isolation from the circulation (10, 
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60). As a result, careful selection of the preferred isolation method is required in MP studies.  As 
our research question was focused on the biological role of MP-derived cholesterol, separation of 
MPs from lipoprotein was a key requirement.  A comparison of the four main methods used for 
MP purification is outlined in table 1.3 overleaf. Differential ultra-centrifugation and density 
gradient ultra-centrifugation methods are insufficient in separating MPs from lipoprotein and 
precipitation methods may influence the biological functions of the purified MPs. For those 
reasons, the method chosen to separate MPs from lipoproteins in this study was SEC. SEC is a 
chromatographic method and molecules are separated by their size. 
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Table 1.3: A Comparison of Methods Used to Isolate Microparticles 
 
 Differential 
ultracentrifugation 
Density gradient 
Ultra-centrifugation 
Size-exclusion 
Chromatography 
Precipitation 
Method Low speed spin of 
1200-2000g for 15-20 
min then a high speed 
spin of 20,000g for 20-
30 min. 
Centrifugation at 1550g for 
20 min to remove cells 
followed by potassium 
bromide density gradient or 
Sucrose gradient/ lodixanol 
gradient. 
Centrifugation at 1550g for 20 
min to remove cells followed 
by a sepharose CL-2B column. 
 
Protein organic solvent 
precipitation, acetate buffer. 
Microparticle 
isolation site 
MPs derived from 
body fluids (plasma) or 
cell culture medium. 
Plasma, human salivary. 
Conditioned medium. 
Platelet, plasma. Plasma, tissue derived from 
central nervous system. 
Advantage It is the most common 
and standard method 
and serves as the 
backbone for other 
methods. 
Separates low-density 
lipoproteins and very low-
density lipoproteins from 
MP based on density. 
Less protein and lipoprotein 
contamination. 
Quick, removes soluble 
protein, inexpensive. 
Disadvantage Contamination from 
proteins and 
lipoproteins can be an 
issue. 
Takes a long time (> 10 
hours). Co-isolation of MPs 
and high-density 
lipoproteins, loss of 
biological function by 
sucrose gradient density. 
Sepharose CL-2B is expensive. The organic solvent used may 
influence the MPs biological 
functions. 
References (61) (62) (63) (18) (57) (64)  
MP: Microparticle 
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1.3 Cholesterol 
1.3.1 Cholesterol structure 
Cholesterol has a molecular formula of C27H45OH and is composed of three features (65): a 
hydrocarbon tail, a ring structure region with four hydrocarbon rings, and a C3 hydroxyl (OH) 
group (Figure 1.2). The four-ring regions present in cholesterol is the signature of all steroid 
hormones (such as testosterone and estrogen). The combination of the steroid ring structure and 
the hydroxyl (alcohol) group classifies cholesterol as a ‘sterol’. The final region is the hydrocarbon 
tail. Like the steroid ring region, this region is composed of carbon and hydrogen atoms. Both the 
ring region and tail region are non-polar. 
 
Figure 1.2 Chemical structure of cholesterol. Cholesterol is composed of three regions; a 
hydrocarbon tail, a ring structure region with 4 hydrocarbon rings and a hydroxyl group on C-3 
(65). 
 
1.3.2 Cholesterol production and regulation 
Cholesterol is a waxy, whitish-yellow fat, which is a crucial building block of cell membranes and 
is also used to make hormones and bile acids (66). It is about 20% of cholesterol in the bloodstream 
comes from food items such as meat, poultry, fish, eggs, milk products, and other animal foods. 
The remainder of our cholesterol in circulation is made by the liver and intestines (67). 
Biosynthesis of cholesterol starts at acetyl coenzyme A and may be divided into three main 
synthesis stages (Figure1.3). Stage one is the synthesis of isopentenyl pyrophosphate, stage two is 
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the synthesis of squalene from six molecules of isopentenyl pyrophosphate and stage three is where 
squalene is converted to form cholesterol. Biosynthesis of cholesterol is regulated by cholesterol 
levels. Intracellular cholesterol is mainly regulated by the protein sterol regulatory element-
binding protein pathways (68, 69). 
 
Figure 1.3 Overview of cholesterol biosynthesis. Cholesterol synthesis starts with acetyl-
coenzyme A (Aceetyl-CoA). Three stages include isopentenyl-pyrophosphate, squalene and 
cholesterol synthesis. 
 
1.3.3 Transport of cholesterol in the plasma 
Lipoproteins are present in the plasma and are essential for the transport of  cholesterol around the 
body (70). Specifically, lipoproteins contain triacylglycerol (TAG), cholesterol, phospholipids and 
apolipoproteins (APOs) (Figure 1.4A). There are five main types of lipoproteins isolated and 
characterised in the blood by centrifugation methods: chylomicrons, very low-density 
lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) 
and high-density lipoproteins (HDL). These vary in size (5–1000nm), protein/lipid composition 
function and in biological role (Figure 1.4). The APOB containing chylomicrons and VLDL 
deliver TAG to cells in the body, while IDL delivers triglyceride and cholesterol. In contrast, LDL 
only delivers cholesterol, and HDL removes excess cholesterol. A lipid profile therefore includes 
total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (71), with each parameter 
having a normal range (Table 1.4). The protein moiety of lipoprotein is known as APO, e.g. 
APOA1, APOB, APOE. Chylomicrons contain APOB48, APOC, and APOE. VLDL molecules 
contain APOB100 and APOE. IDL molecules contain APOB100. LDL molecules mainly contain 
APOB100 whereas HDL mainly contain APOA1. Generally, each LDL particle contains one APOB 
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molecule (72). HDL contains variable amounts of APOA1 with the median content considered 
between one and two per particle (73, 74). The main function of APOA1 is in reverse cholesterol 
transport (75).  
           APOB contains two main isoforms in the plasma: APOB48 and APOB100.  APOB100 is 
composed of 4563 amino acids while APOB48 consists of 2152 amino acids. They both share a 
common N-terminal sequence and APOB48 does not have a C-terminal LDL receptor binding 
region (76). APOB plays an important role in lipoprotein transport. APOE contains 299 amino 
acids and multiple amphipathic α-helices. The N-terminal region forms an anti-parallel four-helix 
bundle and the C-terminal domain contains three α-helices and a LDL receptor-binding site. The 
main function of APOE is transporting lipids, fat-soluble vitamins and cholesterol into the blood 
through the lymph system (77).  It is well understood that APOA1, APOB and APOE are the three 
major APOs that are involved in lipids transportation and metabolism compared to other APOs 
(APOD, APOH, APOM, APOJ). 
 
        
 
 
Figure 1.4 Structure and size of lipoprotein. (A) The structure of lipoprotein: The general 
structure of lipoprotein consists of cholesteryl esters, cholesterol, triglycerides and phospholipids. 
The protein moiety of lipoprotein is known as apolipoprotein (APO) such as APOB and APOA1 
(78). (B) The size and density of different types of lipoproteins (79). 
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Table 1.4: Normal Ranges for Tests Which Make Up a Lipid Profile (71) 
 
      Normal Borderline High 
Total cholesterol 
(mmol/L) 
      
< 5.2 5.2 - 6.2 > 6.2 
LDL cholesterol 
(mmol/L) 
 
< 3.3 3.4 - 4.1 > 4.1 
 Triglycerides 
(mmol/L) 
< 1.7 1.7 - 2.2 > 2.3 
      Poor Better Best 
HDL cholesterol 
(mmol/L) 
< 1 1 - 1.5 > 1.5 
 
LDL: Low-density lipoprotein; HDL: High density lipoprotein 
         
 
1.3.4 Role of cholesterol 
      
There are three types of lipids present in plasma membranes; phospholipids, glycolipids and 
cholesterol (Figure 1.5). The plasma membrane contains more than 90% of cellular cholesterol 
(80). Properties of membrane cholesterol include maintaining cell membrane stability, keeping 
membrane fluid inside the cell and interacting with other biomolecules. Membrane cholesterol is 
widely reported to be involved in multiple diseases (81-82), for example it is known to affect 
Alzheimer’s Disease by influencing AβP1-40 and AβP1-42 peptides cytotoxicity (83). Cholesterol is 
an obligate precursor for many steroid hormones. In addition, cholesterol helps the liver to create 
bile acid that, in turn, aids in the absorption of the fat soluble vitamins A, D, E, and K. 
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Figure 1.5 Cell membrane structure. The cell membrane is a semipermeable phospholipid 
bilayer which contains a variety of biological molecules, primarily proteins (glycoprotein, globular 
protein, surface protein, alpha-helix protein and peripheral protein) and lipids (cholesterol, 
glycolipid and phospholipid) (84). 
 
      
1.3.5 Cholesterol in cardiovascular disease 
Generally, total cholesterol, HDL cholesterol and LDL cholesterol are measured to assess the risk 
of CVD (85, 86, 87, 88). It is well known that LDL cholesterol is the “bad” cholesterol that 
contributes to the progression of CVD, whereas HDL cholesterol on the other hand is often called 
“good” cholesterol because of its’ anti-inflammatory, anti-apoptotic, anti-oxidative (including 
prevention of LDL oxidation), anti-thrombotic and endothelial protective qualities (89). Most work 
has been done around the increased risk of CVD associated with LDL cholesterol, with small dense 
LDL particles being associated with an increased risk of CVD rather than large LDL particles (90). 
Furthermore, small LDL particles can easily penetrate the intimal vessel wall and become exposed 
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to oxidation. Macrophages can then take up oxidised LDL to be a part of atherosclerotic plaque 
(91). Small dense LDL particles have also been associated with endothelial dysfunction (92).  
         HDL cholesterol is known as “good” cholesterol because HDL cholesterol helps remove 
cholesterol from the bloodstream. Additionally, HDL cholesterol may have antioxidant, 
antithrombotic/profibrinolytic and anti-inflammatory properties (93). HDL exerts anti-
inflammatory effects by promoting cholesterol efflux via ABCA1 and ABCG1 (94). Yvan-Charvet 
et al have reported ABCG1 transporter deficient macrophages can increase inflammatory gene 
expression (94). Clinically, statins are used to reduce LDL cholesterol and increase HDL 
cholesterol (95). Interestingly, the development of CETP (cholesteryl ester transfer protein) 
inhibitors which was designed to raise HDL levels failed in phase III of a clinical trial (96). HDL 
cholesterol can, however, turn into “bad” cholesterol according to several studies which showed 
that HDL becomes dysfunctional, even pro-atherogenic in CVD (97, 98, 99). Pan et al report that 
in particular, oxidised HDL reduces the proliferation and migration of endothelial cells which 
greatly contributes to the pathology associated with CVD (100). More recently, Bae et al reported 
low serum total cholesterol (< 4.14mmol/L) or high serum total cholesterol (≥6.21mmol/L) to be 
strongly associated with CVD mortality (101). A recent large Korean study has shown that it is 
unclear whether the association between total cholesterol levels and all-cause mortality varied 
with sex and age (102).  
  Regarding the role of membrane cholesterol in causing cardiovascular dysfunction, the 
following four points should be considered - 1) High levels of cholesterol cause changes to cell 
membrane structure and function; 2) Myocardial contractility, excitability and conduction 
properties have been affected by alterations of membrane cholesterol content; 3) Endothelial 
dysfunction and smooth muscle abnormalities are seen in high cholesterol situations.; 4) High 
cholesterol is associated with the oxidation products of cholesterol. It has also been shown that the 
total cholesterol content of the erythrocyte membrane is positively associated with severe coronary 
artery diseases (103). Furthermore, HDL efflux capacity is also impaired during acute 
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inflammation which may contribute to cholesterol retention in the cell membrane in inflammatory 
disorders (104). Therefore, considering the results of all of these studies, both lipoprotein 
cholesterol and membrane cholesterol have been shown to be involved in the pathophysiological 
processes of CVD. 
 
1.4 Cholesterol Tracers 
As noted above cholesterol is a crucial component of cellular membranes and plays an important 
role in multiple biological functions including cellular signalling and cell metabolism. However, 
the knowledge of cholesterol intracellular dynamics is limited due to the limited availability of 
cholesterol tracers. Cholesterol transport into cells can be studied using radiolabelled cholesterol 
such as 3H-cholesterol (105, 106). Radiolabelled cholesterol methods are not feasible in every 
laboratory and are also very time-consuming. In addition, contamination with a small fraction of 
membranes with high cholesterol content can result in significant errors in cholesterol content 
measurement, therefore, various fluorescent probes of cholesterol have been developed and are 
widely used (106). Various studies make use of filipin, intrinsically fluorescent mimics of 
cholesterol (cholestatrienol and dehydroergosterol), or organic dye-labelled cholesterol analogs 
(NBD-cholesterol, BIODPY-cholesterol) (107). There are drawbacks to each of these methods as 
none truly reflect the physiological function of cholesterol. For example, cells labelled with filipin 
require fixation, so it is not practical to study time-lapse with living cells using this method. In 
addition, filipin labels all cellular cholesterol pools equally, and it is thus difficult to distinguish 
between lipoprotein-derived cholesterol and endogenous-derived cholesterol (107). The high 
photobleaching propensities of cholestatrienol and dehydroergosterol make it a challenging 
prospect to repeat imaging of the samples. For these reasons, organic dye-labelled cholesterol 
analogs have drawn a lot of attention recently, with 22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-23,24-bisnor-5-cholen-3β-ol (22NBDC) and 25-(N-(7-nitro-2-1,3-benzoxadiazol-4-yl) 
methylamino27-norcholesterol (25NBDC) being widely used to study membrane cholesterol (108, 
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109 ). However, based on 22NBDC and 25NBDC chemistry and cell membrane structure, these 
two sensors are inserted in the membrane in a way that could potentially change the ability of 
cholesterol to move in a normal fashion within the cell (110). For example, the rate of 22NBDC 
and 25NBDC exchange between the cell and an acceptor has been shown to be much faster when 
compared to a normal cholesterol exchange rate (110, 111). As an alternative, 3-hexanoyl -7-
Nitrobenz-2- oxa-1,3-diazol-4-yl-cholesterol (3NBDC) is attached to carbon 3 via a C6 spacer, at 
the hydrophilic end of cholesterol (Figure 1.6). The basic chemistry of this molecule means it is 
expected to more appropriately mirror the normal orientation of cholesterol in the membrane and 
recapitulate the interactions with other membrane components such as phospholipids. As part of 
our study is to identify an MP-compatible cholesterol tracer, we explored the use of 3NBDC to 
recapitulate cholesterol movement in various cell systems (THP-1 cells, HMDM cells, HeLa cells 
and HEK 293T cells). 
 
 
  
 
Figure 1.6 The structure of 3-NBD-Cholesterol. The fluorescence tag of 3-hexanoyl- 7-
Nitrobenz-2-oxa-1,3-diazol-4-yl-cholesterol (3NBDC) is attached to carbon 3 via a C6 spacer, at 
the hydrophilic end of cholesterol (112). 
 
 
 
1.5 The Immune System 
The immune system has evolved in vertebrates to protect the body against invading micro-
organisms and the diseases they cause. The foundation of the immune system consists of two 
separate branches: one is specific or adaptive immunity, which is characterised by slow response 
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kinetics and memory, and the other is non-specific or innate immunity which displays rapid 
response kinetics but lacks memory (113). It used to be thought that both these systems acted 
relatively independently although research into innate immune recognition systems has long 
established that there is crosstalk between the two systems which coordinates their action (114, 
115), the links between both systems often impinging on the course that autoimmune diseases take. 
An example of a link between the innate and adaptive immune system was very nicely shown 
during the development of the granulomas which are involves both Toll-like receptor (TLR) and 
Notch activation (116). Interplay between both the innate and adaptive response is crucial in 
mounting an appropriate combined response to invading pathogens. The innate response to 
infection can stimulate the adaptive immune response through the release of cytokines and 
chemokines, which subsequently attract additional cells to the site of infection or induce the 
migration of APCs from the tissues to lymph nodes where naïve T cells can be activated (117). 
Adaptive immune responses contribute to innate immunity by enhancing the antimicrobial 
activities and defence mechanisms of this system (117). 
The early concept of innate immunity was that it non-specifically recognised microbes. 
However the discovery of TLRs in the mid 1990s demonstrated that pathogen recognition by the 
innate immune system is actually reasonably specific, relying on germline-encoded pattern-
recognition receptors (PRRs) that have evolved to detect components of foreign pathogens, 
referred to as pathogen-associated molecular patterns (PAMPs) (118, 119). The main cell types 
involved in innate immunity are natural killer (NK) cells, mast cells, eosinophils, basophils and 
the phagocytic cells such as macrophages, neutrophils and dendritic cells (DCs) (120, 121). Two 
major functions of this system are recruitment of immune cells to sites of infection through the 
production of cytokines and activation of the complement cascade to identify bacteria and promote 
their clearance. Macrophages and DCs routinely take up and present self-antigens, however these 
cells themselves can also become activated by self-antigens such as cell debris as a result of cell 
damage caused by the infection (121,122,123). 
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Rapid induction of type I and II interferon (IFN) expression is a central event in the 
establishment of the innate immune response against viral infection. To trigger IFN expression, 
host cells recognise infection through several families of PRRs, including TLRs, RIG-I-like 
receptors (RLRs), nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs), as 
well as the cytoplasmic sensors of DNA virus infection (124). Following engagement of viral 
sensors by their cognate PAMPs, the host cell activates multiple signalling cascades that stimulate 
an antiviral state, the induction of host restriction factors and the mobilisation of the adaptive arm 
of the immune system (125). The resulting coordinated response disrupts viral replication at 
multiple levels, including the recruitment of NK cells, which provide rapid responses to virally 
infected cells (126). In autoimmunity, these processes may happen in response to self-antigens in 
addition to external antigens (127). 
1.5.1 Toll-like receptors 
TLRs are a class of protein that are critical for both innate and adaptive immune responses to 
recognise specific molecular patterns that are derived from different pathogens (128). TLRs 
include TLR1-13 in mammals, with TLR1-10 being found in humans while TLR1-9 and TLR11-
13 are found in mice (129). TLRs are generally located on the plasma membrane with the exception 
of TLR3, TLR7, TLR8 and TLR 9, which are located in the endosomal compartment (Figure 1.7). 
TLR expression has been found on many different immune cells, including T cells, B cells, 
monocytes and macrophages (Table 1.5) (129,130). As described in Table 1.5, TLR4 is widely 
expressed on macrophages and monocytes (130), therefore, THP-1 cells (a human monocytic cell 
line) and human monocytes derived macrophages (primary macrophages) were used as cell models 
in this study.  Data from human patients and animal models of autoimmune diseases indicate that 
inappropriate triggering of TLR pathways might cause an autoimmune reaction and tissue damage 
by releasing inflammatory cytokines, chemokines and other biomolecules (131). Aberrant TLR 
signalling has been implicated in a variety of autoimmune diseases such as Sjögrens Syndrome 
(SS), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and Multiple Sclerosis 
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(MS) (132). Therefore, the influence of autoimmune diseases (SLE/RA) derived MPs on TLR4 
expression in vitro and ex vivo cell models was one part of this study. 
 
Figure 1.7 Locations of human toll-like receptors. TLR1, 2, 4, 5, 6 and 10 are located on the 
plasma membrane. TLR 3, 7, 8 and 9 are located within the endosomal compartment (133). 
 
 
 
Table 1.5 The Expression Pattern of Human Toll-like Receptors on Immune Cells (130) 
 
TLR Expression on immune cells 
1 Monocytes, macrophages, Bcells, Tcells, DCs, PMN, NK cells 
2 PMN, DCs, monocytes, macrophages 
3 DCs, NK cells, macrophages, mast cells 
4 Macrophages, DCs, Monocytes, PMN 
5 Monocytes, DCs, T cells, PMN, macrophages 
6 Monocytes, macrophages, B cells, T cells, DCs, PMN, NK cells 
7 B cells, plasmacytoid DCs 
8 Monocytes, myeloid DCs 
9 B cells, plasmacytoid DCs,  
10 B cells; plasmacytoid DCs 
TLRs: Toll-like receptors; DCs: Dendritic cells; PMN: Polymorphonuclear leucocyte; NK: Natural Killer; 
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TLRs are a class of PRRs that are activated subsequent to the recognition of PAMPs and damage-
associated molecular patterns (DAMPs) (134). A series of processes not only trigger host innate 
immune responses but also host adaptive immune responses (135). TLRs interact with their 
respective PAMPs and DAMPs and combine with co-receptors or molecules to form a homo- or 
heterodimer to initiate downstream signalling pathways (135). TLRs are composed of an 
ectodomain which recognises PAMPs and DAMPs, a transmembrane domain and a cytoplasmic 
Toll/IL-1 receptor (TIR) domain which binds MyD88 and TRIF, two adaptor proteins (136). When 
TLRs recognise PAMPs and DAMPs, MyD88 or TRIF is activated which results in downstream 
phosphorylation events culminating in the activation of NF-κB or interferon regulated factors 
(IRFs) and production of  pro-inflammatory cytokines and type I IFN which protect the host from 
microbial infection (Figure 1.8) (136, 137). 
 
Figure 1.8 Toll-like receptor signalling pathways. Activation of the MyD88 or TRIF signalling 
pathways downstream of Toll-like receptors (TLRs) results in pro-inflammatory cytokine 
production or type I interferon production respectively (137). 
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1.6 Autoimmune Disorders 
Autoimmune disorders are multifactorial diseases characterised by an abnormal immune response 
to reactive self-antigens by T and B cells, resulting in chronic inflammation (138). Inflammation 
in autoimmune disorders can involve multiple organs, leading to systemic autoimmune diseases, 
such as SS, RA, SLE, systemic sclerosis (SSc) and primary biliary cirrhosis to name but a few 
(139). 
1.6.1 Systemic Lupus Erythematosus 
SLE is a multi-organ autoimmune disease that often results in end-organ failure (140). Redundant 
autoantibodies are produced against self-antigens that are located in the nucleus of cells, with 
genetic, environmental and hormonal factors contributing to the occurrence of SLE (141). SLE 
occurs worldwide, with most cases seen in women of childbearing age. The pathogenesis of SLE 
is complex, with key events resulting in the increased presence of apoptosis-related endogenous 
nucleic acids which subsequently stimulate IFNα production and promote autoimmunity by 
breaking self-tolerance through the activation of APCs (Dendritic cells, B cells), following the 
amplification of immune complexes and inflammation (142) (Figure 1.9). Aberrant innate immune 
responses play a key role in the pathogenesis of SLE, which contributes to tissue injury and 
aberrant activation of autoreactive T and B cells (143). Autoreactive T and B cells activation leads 
to autoantibody production and end-organ injury (143). 
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Figure 1.9 Pathogenic mechanisms of Systemic Lupus Erythematosus. Different 
subpopulations of immune cells, immune complex and cytokine interplay contributes to disease 
progression and leads to end organ failure (kidneys and heart). Ab, antibody; BAFF, B-cell 
activation factor; DC, dendritic cell; IC, immune complex; IFN-I, interferon-I; IL-10, interleukin-
10; MΦ, macrophage; MHC, major histocompatibility complex; self-Ag, self-antigen; TCR, T-
cell receptor; TGF-β, transforming growth factor-beta (142). 
      
The diagnosis of SLE is based on a combination of clinical symptoms and positive serologies. SLE 
has heterogenous clinical manifestations, resulting in the development of several classification 
criteria such as the Systemic Lupus International Collaborating Clinics (SLICC) criteria (144) 
(Table 1.6). Assessing SLE disease activity is an integral part of diagnosis, with many patients 
continuing to suffer from disease effects even after being provided with appropriate treatment 
(144). Several sets of indices have been developed and used as a clinical index for the measurement 
of SLE, such as the Systemic Lupus Activity Measure (SLAM) and Systemic Lupus Activity Index 
(SLEDAI). SLEDAI is used as a global index due to its validity, reliability and sensitivity, 
consisting of 24 weighted clinical and laboratory variables of nine organ systems. Manifestation 
items are weighted with scores ranging from 1 to 8 (145) (Table 1.7). SLE patients with a SLEDAI 
score ≥ 6 are considered to have “active” disease. For the clinical management of SLE, there is no 
effective medicine that is conducive to treatment; rather the approach combines 
immunomodulators, facilitates immunosuppression and prevents organ damage. 
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Table 1.6: Systemic Lupus International Collaborating Clinics Criteria (144)  
 
Clinical Features Immunologic Features 
Acute cutaneous lupus  
(maculopapular lupus rash, malar rash, 
photosensitive lupus rash, etc) 
High ANA concentration 
Chronic cutaneous lupus  
(discoid rash, mucosal lupus, etc.) 
High anti-dsDNA antibody concentration 
Oral or nasal ulcers Presence of anti-Sm 
Non-scarring alopecia Positive APA 
Synovitis in 2 joints Low complement (C3,C4,CH50) 
Serositis Direct Coombs test 
Renal (urine protein or RBC casts) Must have a total of 4 features with  1 clinical 
feature and 1 immunologic feature or biopsy-
proven LN with anti-dsDNA antibodies or ANA 
Neurologic (seizures, psychosis, other)  
Haemolytic anaemia  
Leucopoenia or lymphopenia  
(without an identifiable cause) 
 
Thrombocytopenia ) 
without an identifiable cause) 
 
ANA: antinuclear antibody; APA:antiphospholipid antibody; dsDNA:double-stranded DNA; LN:Lupus nephritis; 
SLICC:Systemic Lupus International Collaborating Clinics; Sm:Smith. 
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Table 1.7: Systemic Lupus activity index scores (145) 
 
SLEDAI Yes No Descriptor Definition 
8 1 0 Seizure Recent onset. Exclude metabolic, infectious or drugs 
causes. 
8 1 0 Psychosis Altered ability to function in normal activity. Include 
hallucinations, incoherence, marked loose associations, 
marked illogical thinking, bizarre, disorganised, or 
catatonic behaviour. 
8 1 0 Organic brain syndrome Altered mental function, impaired orientation, memory 
or other intellectual function, rapid onset and 
fluctuating clinical features. 
8 1 0 Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal 
haemorrhages, serous exudate or haemorrhages in the 
choroid or optic neuritis. 
8 1 0 Cranial nerve disorder New onset of sensory or motor neuropathy involving 
cranial nerves. 
8 1 0 Lupus headache Severe, persistent headache; may be migranious, but 
must nonresponsive to narcotic analgesia. 
8 1 0 CVA New onset of cerebrovascular accident(s). Exclude 
arteriosclerosis 
8 1 0 Vasculitis Ulceration, gangrene, tender finger nodules, periungual 
infarctions, splinter haemorrhages, or biopsy or 
angiogram proof of vasculitis. 
4 1 0 Arthritis More than 2 joints with pain and signs of inflammation 
4 1 0 Myositis Proximal muscle aching/weakness, associated with 
elevated CPK/aldolase/EMG changes/biopsy showing 
myositis 
4 1 0 Urinary casts Leme-granular or red blood cell casts 
4 1 0 Haematuria >5 red blood cells/high power field. 
Exclude stones, infection, other. 
4 1 0 Proteinuria >0.5mg/24hours. 
4 1 0 pyuria >5 white blood cells/high power field. 
Exclude infection. 
2 1 0 Rash Inflammatory type rash. 
2 1 0 Alopecla Abnormal patchy or diffuse loss of hair. 
2 1 0 Mucosal ulcers Oral or nasal ulcerations. 
2 1 0 Pleurisy Pleuritic chest pain with pleural rub or effusion,or 
pleural thickening. 
2 1 0 Pericarditis Pericardial pain with at least 1 of the following: rub, 
effusion, or positive ECG or echo 
2 1 0 Low complement Decrease in CH50. C3 or C4 below the lower limit of 
normal for testing. 
2 1 0 Increased DNA binding Increase DNA binding above normal range for testing 
laboratory. 
1 1 0 Fever >38 degrees C, exclude infectious cause. 
1 1 0 Thrombocytopenia <100 x 109 platelets/L, exclude drug causes. 
1 1 0 Leucopenia <3 x 109 WBC/L, exclude drug causes. 
 
1.6.2 Rheumatoid Arthritis 
RA is a systemic, autoimmune inflammatory disease which is characterised by damaged synovial 
joints which leads to deformity and disability (146). The disease is caused by the immune system 
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attacking healthy body tissue, but what triggers it remains unclear. Some risk factors may 
contribute to the occurrence of RA such as family history, obesity, age, and smoking (147). There 
are two major subtypes of RA based on the presence or absence of anti-citrullinated protein 
antibodies (148). The pathological processes of RA involves T cells, B cells, DCs, macrophages, 
cellular cytokines and cell surface molecules. The complex pathogenesis of RA is summarised in 
figure 1.10 (148). Genetic and environmental factors disturb peptide citrullination, followed by 
APCs (macrophages and DCs) and fibroblast-like synoviocytes being activated which results in 
local inflammation and antigen presentation. This ultimately leads to activation of the innate 
immune system and severe organ damage (148). Aberrant intracellular signalling pathways may 
contribute to the development of RA. Cytokines, chemokines, antibodies and antigens that 
contribute to inflammation bind to receptors on the cell surface of immune cells. Once receptors 
are bound, a cascade of intracellular signalling is initiated which ultimately results in pro-
inflammatory gene expression (149). Overall, immune activation and RA disease progression is a 
complex process that involves both adaptive and innate immune systems (149).  
 Criteria for RA diagnosis include patients having at least one joint with swelling and/or a 
number of small joints involved, in which case the joint swelling cannot be explained by another 
disease (146). Patients with diagnosis of inflammatory arthritis with the presence of rheumatoid 
factor, anti-citrullinated protein antibodies, elevated C-reactive protein (CRP) levels, or an 
erythrocyte sedimentation rate (ESR) (150), also suggest the patient has RA. Diagnostic criteria 
are shown in Table 1.8, according to the American College of Rheumatology/European League 
against Rheumatism. Treatment of RA aims to control the inflammation of synovitis and prevent 
joint injury. Medicine-based therapies include nonsteroidal anti-inflammatory drugs, anti-
rheumatic drugs, immunosuppressants and corticosteroids, depending on disease activity and the 
sensitivity of patients to certain drugs. 
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Figure 1.10 Disease mechanisms in Rheumatoid Arthritis. Genetic and environmental factors 
disturb peptide citrullination to produce anticitruline antibodies, followed by immune cells 
activation (T cells, B cells, macrophages and dendritic cells) leading to organ damage (148). 
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Table 1.8: Rheumatoid Arthritis Diagnostic Criteria (151) 
 
CRITERIA SCORE 
Target population (who should be tested?): patients who: 
1) have at least one joint with definite clinical synovitis (swelling) 
2) with the synovitis not better explained by another disease 
 
Classification criteria for RA (score-based algorithm: add score of 
categories A through D; a score of ≥ 6 out of 10 is needed for 
classification of a patient as having definite RA): 
 
A. Joint involvement  
One large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
> 10 joints (at least one small joint) 5 
B. Serology (at least one test result needed for classification)  
Negative RF and negative ACPA 0 
Low positive RF or low positive ACPA 2 
High positive RF or high positive ACPA 3 
C. Acute phase reactants (at least one test result needed for 
classification) 
 
Normal CRP and normal ESR 0 
Abnormal CRP or normal ESR 1 
D. Duration of symptoms  
< six weeks 0 
≥ six weeks 1 
ACPA = anti-citrullinated protein antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RA 
= Rheumatoid Arthritis. 
 
 
1.6.3 Cytokine production in autoimmunity 
Inflammation is caused by the interplay of pro-inflammatory and anti-inflammatory cytokines 
(152). Understanding the exact physiological role of these cytokines in inflammation and their 
pathogenic role in disease status is essential for the foundation of new therapies in autoimmune 
conditions. Generally, the pro-inflammatory factors include interleukin- 6 (IL-6), IL-8, tumour 
necrosis factor alpha (TNFα), IFN, IL-13/17 and B-cell activation factor. Anti-inflammatory 
cytokines include IL-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11 and IL-13. These cytokines 
are produced by macrophages and other immune cells. Human TNFα is a non-glycosylated protein, 
and the TNFα gene is located on chromosome 6p23-6q12. TNFα exists both in soluble and 
membrane bound forms (153). TNFα is not only a powerful regulator of pro-inflammatory 
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cytokines but also increases lipid transduction mediators (154). TNFα signals through two 
transmembrane receptors, TNFR1 and TNFR2, and regulates a number of critical cell functions 
including cell proliferation, survival, differentiation, and apoptosis (155). Macrophages are the 
major producers of TNFα and interestingly are also highly responsive to TNFα (155). Aberrant 
TNFα production and TNF receptor signalling have been associated with the pathogenesis of 
several diseases, including RA, Crohn’s disease, atherosclerosis, psoriasis, sepsis, diabetes, and 
obesity (155). TNFα has been shown to play a pivotal role in orchestrating the cytokine cascade 
in many inflammatory diseases and because of this role as a “master-regulator” of inflammatory 
cytokine production, it has been proposed as a therapeutic target for a number of diseases. Indeed 
anti-TNFα drugs are now licensed for treating certain inflammatory diseases including RA and 
inflammatory bowel disease (156). Studies have shown that TNFα blockers reduce the number of 
infiltrating synovial granulocytes and macrophages and reduce chemokine IL-8 and monocyte 
chemotactic protein-1 in RA (157). This type of treatment however is not advised in all 
autoimmune conditions as TNFα blockers can also block the immunoregulatory and anti-apoptotic 
effects of TNFα in conditions such as SLE and so is ill-advised in this case (158). 
 
1.7 Microparticles in Autoimmune Disorders 
It is well known that TNFα stimulates the release of MPs, with recent studies showing MPs as 
substrates for inflammation (159). Furthermore, other studies have also shown MPs induce, 
amplify and maintain the process of inflammation by combining with other inflammatory factors 
(159, 160, 161, 162). Due to the diversity of MP content and biological function, specific parts of 
MPs have also been shown to have anti-inflammatory functions (163). Whether the MP produced 
has pro-inflammatory or anti-inflammatory properties appears to be dependent on the stage of the 
disease. 
Increased levels of pro-inflammatory cytokines (IFN and TNFα) are observed in SS patients (164, 
165), suggesting inflammation plays an important role in SS pathology. Although there are few 
 35 
studies reporting the role of MPs in SS, Sellam et al report that both platelet and leucocyte-derived 
MPs are increased in SS patients, implying that MPs may play a role in the process of inflammation 
in SS (166). More recently, a study reported that endothelial MPs are directly correlated with SS 
duration, explicitly suggesting that endothelial MPs are involved in the pathogenesis by 
participating in the processes of inflammation and endothelial dysfunction (167). Further studies 
are needed to highlight the precise mechanisms which MPs play in SS and to assess if MPs can 
act as an inflammatory indicator in this disorder.  
Psoriasis is a chronic inflammatory disorder leading to skin and joint injury (168). Several 
studies report that the levels of both endothelial- and platelet-derived MPs are increased in 
psoriasis patients (169, 170). Reports imply that MPs are involved in the activation of 
inflammation and endothelial dysfunction which leads to increased CVD risk in these patients 
(170). Furthermore, another study supports previous studies and reports that the level of MPs from 
endothelial cells, platelets and monocytes is increased (171), further suggesting that MPs aggravate 
the development of psoriasis by leading to the activation of inflammation and endothelial 
dysfunction. More recently, Pirro et al have demonstrated that endothelial MPs are correlated with 
systemic inflammation (172). Another study suggests platelet MPs and endothelial MPs are 
significantly reduced when TNFα is blocked in psoriasis patients (173), and suggests TNFα may 
induce MP release to initiate inflammatory activation and increase CVD risk in psoriasis. Further 
studies are needed to illuminate how MPs, derived from different cell types, do in fact regulate the 
inflammatory process in psoriasis. 
1.7.1 Microparticles and Systemic Lupus Erythematosus 
SLE is a chronic inflammatory autoimmune disease which affects almost all organs in the body. 
As a result of this, the pathophysiology of SLE is complex and involves a multifactorial response 
with studies confirming inflammation plays a vital role during the process (174). There is, 
therefore, a rationale in finding an inflammatory indicator which could be used to monitor disease 
progression or which could function as a druggable target. Recently MPs have been implicated in 
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many diseases involving inflammatory processes, however, there are still limited studies directly 
reporting MPs as an inflammatory indicator in SLE, with the role that MPs play in SLE patients 
still being argued (175). One study reports endothelial MPs do not show any significant difference 
between SLE patients and healthy people (176). On the other hand, Parker et al report that 
suppressing inflammation can in fact reduce the levels of endothelial derived MPs in SLE 
suggesting there is a clear link between MPs and the inflammatory process in this condition (177). 
The heterogeneous nature of SLE in addition to patients entering disease flares versus being quite 
well may be the reason why studies yield different results regarding the role which MPs play in 
the disease process. Some authors find similar endothelial MPs levels between SLE patients and 
healthy controls, when disease activity is controlled, aligning with the idea that inflammation is 
one of the mechanisms of endothelial dysfunction (177). Another study reports that the levels of 
CD54+ endothelial MPs in SLE patients is higher than in healthy controls (178). This study 
mentions several reasons why other papers did not find significant differences in other endothelial 
MP markers (CD62E, CD51, CD146) with reasons including the different techniques employed in 
MP isolation, in addition to endothelial activation or apoptosis (178). Overall these studies confirm 
the heterogeneous nature of MPs and suggest the need for further work to investigate the usefulness 
of MPs in monitoring inflammatory processes and endothelial dysfunctional in SLE.  
More recently, one study has shown monocyte MP levels to be much higher in SLE active 
patients compared to inactive patients (p<0.05), however endothelial cell MPs, platelet MPs and 
B lymphocyte MPs showed no significant difference between both groups (179). It is well 
understood that IFNα is a major inflammatory factor in SLE, with Niessen et al reporting that 
IFNα and apoptotic-cell-derived MPs together can amplify and maintain inflammation (180). A 
more recent study further reports endothelial MPs and partial granulocyte MPs increase the 
expression of pro-inflammatory cytokines in SLE patients (181). Different results observed in the 
above studies discussed may be due to SLE disease activity in addition to the heterogeneous nature 
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of MPs and knock on diverse biological function, even relating to MPs derived from the same cell 
type. Further studies are required to evaluate the potential of MP inflammatory indicators in SLE. 
1.7.2 Microparticles and Rheumatoid Arthritis 
RA is a chronic progressive autoimmune disease with unknown aetiology, causing inflammation 
in the small joints which results in their deformity and immobility (182). Currently, there is limited 
research directly reporting MP involvement in RA associated inflammation, with studies generally 
involving MPs derived from the plasma and synovial fluid of RA patients. In 2002, pioneering 
research in the field reported that platelet MPs were increased and related to disease activity in RA 
(183). Although this study indirectly reports that MPs are involved in the inflammatory process in 
RA, the mechanism by how they do this is still poorly understood. The direct role which MPs play 
in the inflammatory response in RA was not reported until 2005 when a subsequent study 
suggested that MPs derived from synovial fluid increased the levels of inflammatory chemokines 
and cytokines such as IL-6 and IL-8 (184). A later study discovered one of the mechanisms of 
leukocytapheresis related to decreased platelet MPs and increased granulocyte-derived MPs, also 
indicating that MPs play a key role in the inflammatory response seen in RA (185). On the other 
hand, MPs derived from different cells types play different biological functions, with platelet MPs 
releasing inflammatory cytokines and granulocyte-derived MPs increasing anti-inflammatory 
cytokines, suggesting the complicated biological functions of MPs (185). More recently, an in-
vitro study involving different cell-derived MPs from plasma and urine in RA patients reported 
that MPs are highly associated with disease activity and release of IL-1, IL-17 and TNFα (179). 
Considering the above studies, it appears that MPs play a key role in the inflammatory process in 
RA, but the precise mechanism of how they do this still remains elusive. 
 
1.8 Cholesterol in Autoimmune Disorders 
Cholesterol plays an important role in cellular and systemic metabolism involved in the regulation 
of immune cell activity (186,187). The major part of cellular cholesterol is located in the cellular 
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membrane in particular the lipid raft region is enriched with cholesterol (188). To date, previous 
studies have shown that the lipid raft plays an essential role as a signalling pathways. Several 
studies have demonstrated that TLR4 and T cell receptor (TCR)-mediated immune activation and 
pro-inflammatory responses are suppressed by cholesterol depletion from the lipid raft, while 
cholesterol loading has the opposite effect (186, 189). Furthermore, Tall et al reported that 
activation of TLR signalling results in reduced cholesterol efflux, which leads to cholesterol 
accumulation and amplification of the inflammation response (189).  Yvan-Charvet et al have also 
shown free cholesterol accumulation and an increased in TLR signalling in ABCG1 transporter 
deficient macrophages (94). A number of studies have indicated that lipid abnormalities are 
observed in autoimmune diseases such as SLE and RA, with one study reporting that low HDL 
cholesterol is associated with a higher risk of autoimmune disease development (190, 191). 
Abdalla et al reported that there are significantly higher cholesterol and LDL cholesterol levels in 
SLE patients with lupus nephritis when compared to SLE patients without lupus nephritis (192). 
Although the exact mechanisms have not been elucidated, one study shows that the functional 
properties of HDL play a key role in inflammatory pathophysiology properties of HDL (193). 
Specifically, in an acute-phase response of inflammation, APOA1 (which is the major protein 
component of HDL) is replaced by other acute-phase proteins, like SAA protein. SAA protein can 
promote the pro-inflammatory properties of HDL (193). The pathogenesis associated with the 
dyslipidaemia in SLE is shown in figure 1.11. Multiple pathogenic mechanisms are suggested, 
including antibodies against lipoprotein lipase and the balance between pro-atherogenic 
lipoproteins and anti-atherogenic lipoproteins being affected by cytokines (194). 
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Figure 1.11 Lipid metabolism abnormalities have been shown in Systemic Lupus 
Erythematosus. 1): Antibodies against lipoprotein lipase (LPL) may decrease the ability to 
degrade chylomicrons. 2): Removal of chylomicrons is delayed. 3): & 4): HDL dysfunction (194). 
      
It is well-known that autoimmune patients are at a higher risk of CVD (195). However, little is 
known of the underlying mechanism. Generally, it is accepted that high total cholesterol and high 
LDL-C increases risk of CVD. Interestingly, dyslipidaemia is sometimes present in RA, with 
patients often showing low total cholesterol and low HDL-C when compared to that of the general 
population (196). Elena et al have reported low LDL-C and low total cholesterol is associated with 
CVD risk (197). Although a mechanistic explanation is lacking. Studies have suggested that the 
reason for this lipid paradox is inflammatory effects influencing lipid ratio (196). A recent study 
by Huang et al  has suggested that one of the principal causes of CVD in mice with psoriasis-like 
conditions was cholesterol trapped in inflexible vessels walls, which inevitably led to CVD (198). 
Taken together, these studies suggest that cholesterol may contribute to the disease processes 
observed in autoimmunity. 
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1.9 Overall Aims of the Study 
● Optimise a method for the estimation of cholesterol in circulating MPs from platelet 
concentrates 
● Establish a reference range for MP cholesterol (MPC) in a healthy representative 
population group 
● Investigate the potential of MPC as a biomarker in autoimmune disorders (SLE and RA) 
● Characterise inflammatory properties of MPs derived from autoimmune disease patients in 
in vitro and ex vivo models 
● Develop 3NBDC as a versatile membrane cholesterol tracer 
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2.0 Materials and Methods 
 
 
 
      
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
2.1 Sample Collection 
2.1.1 Processing of platelet concentrates 
Platelet concentrates were obtained from the Irish Blood Transfusion Service in St James Hospital. 
A 50ml aliquot of this concentrate was centrifuged at 879g for 10 minutes to remove platelets. 
This procedure was repeated three times before the supernatant was finally centrifuged at 879g      
for 5 minutes to remove residual platelets completely. The platelet-free supernatant (PFS) was 
aliquoted into 1.5ml sized fractions and stored at -80℃. 
2.1.2 Processing of whole blood 
Fasting (at least 12 hours) or non-fasting blood samples were collected from healthy volunteers 
from the student and staff population of TU Dublin. Patients with autoimmune conditions (SLE 
and RA) were recruited from clinics in Beaumont Hospital.  Written informed consent was 
obtained from each donor under TU Dublin (DIT) REC-16-49 and Beaumont hospital reference 
REC-17-17. In all cases, venous blood samples were collected into 3.5ml sodium citrate tubes 
(vacutainer) using a 21 gauge needle. All blood samples were anonymised with a unique code 
according to the order of blood draws taken. All samples were processed by the same operator 
within 4-6 hours after blood collection. Briefly, samples were centrifuged at 1,500g for 10 minutes 
at room temperature to collect platelet poor plasma (PPP). PPP was then centrifuged at 13,000g 
for 10 minutes at 4℃ to remove any remaining platelets. This platelet free plasma (PFP) was 
aliquoted into 1.5ml eppendorf tubes and stored at -80℃. 
 
2.2 Microparticle Preparation 
2.2.1 Size-exclusion chromatography 
A 10ml volume of Sepharose CL-2B 300 (Sigma) was washed three times with PBS containing 
0.32% trisodiumcitrate (pH 7.4, 0.22 µm filtered). A 10ml syringe was then packed with washed 
Sepharose CL-2B to create a column as described previously in Boing et al (63). Each column was 
used only once (Figure 2.1). 
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Figure 2.1 Sepharose column used to collect fractions. Up to 35 fractions were collected using 
this SEC method. Sample volume loaded onto the column was either 1.5ml or 0.5ml. 
 
      
2.2.2 Collection of fractions 
PFS (1.5ml) from the platelet concentrate or PFP (1.5ml/0.5ml) from donors was loaded onto the 
sepharose column, followed by elution with PBS/0.32% citrate (pH 7.4, 0.22µm filtered). In all 
cases, the elute was collected in 30-35 fractions of approximately 450µl in size. All fractions were 
stored at -80℃ for later batch analysis. Chapter 4 is mainly focused on characterising fractions 8-
13 as these fractions are lipoprotein deficient.  
 
2.3 Microparticle Size Analysis 
2.3.1 Dynamic light scattering      
MP size was determined using the Malvern Zetasizer ZS. The Malvern system determines the size 
of particles by measuring the speed of particles undergoing Brownian motion in a sample using 
Dynamic Light Scattering (DLS). A schematic figure of the DLS technique is shown in Figure 2.2. 
Briefly, 50µl samples from fractions 8-13 were diluted in 1ml of 0.32% PBS/citrate and were 
measured at 10℃. The number distribution or intensity distribution function was applied to analyse 
MP size. The intensity distribution function is naturally weighted based on the scattering intensity 
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of each fraction’s particles. The intensity distribution is sensitive to the presence of large particles. 
The number distribution provides the relative distribution from the different size in terms of how 
many particles there are, which are derived from the intensity distribution using Mie theory (199). 
 
Figure 2.2 The Principle of Dynamic Light Scatter. The sample is contained in a cuvette and 
the scattered light of the incident laser can be detected at different angles. The scattered light is 
dected at a certain angle over time and the signal is used to determine the particles size by 
theStokes-Einstein equation (200). 
 
2.3.2 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is the method used to visualise and measure nanoparticles 
in suspension in the range from 10-1000nm and is again based on the analysis of Brownian motion. 
A schematic figure of the NTA technique is shown in Figure 2.3. Briefly, a representative fraction 
from the platelet concentrate and donor plasma was measured using NTA (Nanosight LM10). 
Fractions were diluted 5-100 fold in PBS to reduce the number of particles in the field. Camera 
level was set to 14 and the detection threshold was 32. The analysis was performed by the 
instrument software NTA. In some cases, NTA (NS300) was used to measure fractions 8-13 MP 
size. In those cases, the camera level was set to 9, threshold 9 and screen gain 4.0. At least three 
recordings were performed for each fraction. 
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Figure 2.3 Schematic diagram of Nanoparticle Tracking Analysis. The particles are suspended 
in liquid and detected by a laser beam (201) 
 
2.3.3 Transmission electron microscopy 
To visualise MPs, 5µl of the sample from each fraction 8-13 was placed on a 200-mesh formvar 
and carbon coated copper grid (Ted Pella) and allowed to adhere for 10 minutes at room 
temperature. Excess sample was wicked away with filter paper and the grid was floated on a 20µl 
drop of EM Stain 336 (Uranyl Acetate Alternative) (Agar Scientific) diluted 1:4 with distilled 
water. Excess stain was wiped away with filter paper to leave a dry grid. Images were acquired 
using a Hitachi H7650 transmission electron microscope operating at 100 kV and side mounted 
camera. 
 
2.4 Flow Cytometry 
Flow cytometry is a technique used to detect and measure physical properties (size and internal 
complexity) and fluorescence characteristics of cells or particles. For conventional flow cytometry, 
the limit of detection is around 300nm. A schematic figure of the flow cytometry technique is 
shown in Figure 2.4. Briefly, cells or particles are suspended in a fluid and injected into the flow 
cytometry instrument. The detection of cells or particles is performed by passing them through a 
flow chamber with one or several laser beams. Cells or particles are often labelled with 
fluorescence markers so that fluorescent signal emissions can be detected. The data gathered are 
processed by a computer. The resulting information is usually displayed in dot-plots or histograms. 
 46 
 
Figure 2.4 Schematic diagram of flow cytometry (202) 
 
 
2.4.1 Microparticles 
 
In the case of fractions from platelet concentrates, 20µl of each fraction 9-12 was incubated with 
5µl phycoerythrin (PE)-labelled anti-CD61 (catalogue number 555754, BD Biosciences) for 45 
mins on ice. In the case of fractions from donor plasma, 20µl of each fraction 8-13 was incubated 
with one of the following fluorescent monoclonal antibodies: 5µl phycoerythrin (PE)-labelled anti-
CD61 (catalogue number 555754, BD Biosciences), 5µl phycoerythrin (PE)-labelled anti-CD45 
(catalogue number 555483, BD Biosciences), 4µl Fluorescein isothiocyanate (FITC)-labelled anti-
CD235a (catalogue number 559943, BD Biosciences), 5µl phycoerythrin (PE)-labelled anti-31 
(catalogue number 555446, BD Bioscience) and 5µl Allophycocyanin (APC)-labelled anti-CD42b 
(catalogue number 551061, BD Bioscience) for 45 mins on ice. Thereafter, all samples were 
incubated at room temperature for 20 minutes, diluted with 300µl PBS/Citrate and analysed by 
flow cytometry on the Accuri C6 (Accuri Cytometers). For flow cytometry analysis of MPs, events 
calibrated by internal standard beads (0.8µm; Sigma) were identified in forward-scatter and side-
scatter intensity dot representation, gated as the MPs, and plotted on one colour fluorescence 
histograms. For MP numeration, Accuri C6 automatically calculated counts per µl for gated 
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populations. The direct counts correlated highly (r2=0.999), and are as precise as counts performed 
with counting beads. Unstained samples and isotype control antibodies were used as negative 
controls in all measurements. Additionally, fluorescence minus one (FMO) controls were used to 
identify CD31+ or CD42b+ MP in CD31/CD42b double staining analysis. 
 
2.4.2 Cells 
Post MP or LPS treatment, THP-1 cells or HMDMs were washed twice with PBS and re-suspended 
in 100µl of PBS containing 2% FBS, before staining with 5µl of APC-anti-human CD284 (TLR4) 
(BioLegend) for 45 minutes on ice. After being washed twice with PBS, cells were finally 
resuspended in 400µl of PBS containing 2% FBS. Unstained samples were used as a negative 
control. Flow cytometry was performed on the Accuri C6 (Accuri Cytometers). 
 
2.5 Estimating Cholesterol Concentration 
2.5.1 Donor plasma and microparticles isolated from platelet concentrate 
For quantitative determination of total cholesterol in donor plasma and in MPs isolated from 
platelet concentrates, a manual colorimetric cholesterol assay was applied (Cholesterol assay, 
AUDIT Diagnostic, Randox). Total cholesterol levels in donor plasma and in MP fractions 9-12 
were estimated. Briefly, 10µl of plasma or each fraction/standard was added to a 1ml cuvette 
followed by 1ml of cholesterol kit reagent. The samples were incubated for 10 minutes at 
37℃	before being read spectrophotometrically at 500nm. The concentration of cholesterol was 
calculated using the formula:  
#$%&'$()*+	&,	%(-./+	0	1&)*+)2'(23&)	&,	24+	%2()5('5#$%&'$()*+	&,	%2()5('5  
 
2.5.2 Microparticles isolated from donor plasma 
The manual colorimetric cholesterol assay was not sensitive enough to estimate cholesterol levels 
in MPs from plasma, so instead the Amplex® Red Cholesterol Assay Kit (A12216, Invitrogen) 
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was applied to donor plasma fractions. This kit is based on a fluorometric method for detecting 
very low concentrations of cholesterol. The cholesterol concentration of fractions from all donor 
samples was determined according to the manufacturer’s instructions. Batch analysis was carried 
out on samples. 
 
2.6 Estimating Triglycerides Concentration in Donor Plasma 
Triglyceride levels were estimated in donor plasma using a manual colorimetric triglycerides assay 
(Triglycerides assay, AUDIT, Diagnostic, Randox). Briefly, 10µl of each plasma /standard was 
added to a 1ml cuvette followed by 1ml of triglyceride kit reagent. The samples were incubated 
for 5 minutes at 37℃ before being read spectrophotometrically at 505nm. The concentration of 
triglyceride in each fraction was calculated using the formula:  
#$%&'$()*+	&,	%(-./+	0	1&)*+)2'(23&)	&,	24+	%2()5('5#$%&'$()*+	&,	%2()5('5  
 
 
2.7 Microparticle Lipoprotein Estimation 
2.7.1 Immunoblotting 
Dot blots using antibodies to various APOs were used to evaluate the lipoprotein content of 
fractions 8-13. A schematic figure of the dot blot technique is shown in Figure 2.5. Briefly, 2µl of 
each fraction sample from platelet concentrates or donor plasma was spotted onto a nitrocellulose 
membrane. The membrane was blocked with 5% Bovine Serum Albumin (BSA) for 1 hour at 
room temperature, followed by incubation with a primary antibody for 1 hour at room temperature. 
All primary antibodies used were from Mabtech AB, diluted to the following concentrations in 5% 
BSA: APOA1 (mAb HDL-44-biotin, batch 7,code 3710-6) (1:1000), APOB (mAb LDL-11-biotin 
code 3715-6 Batch 7) (1:5000), APOH (mAb H464-biotin,Batch 1 3711-6) (1:1000), APOJ (J100-
biotin) (1:1000), APOM (M5-biotin) (1:1000), APOD (D544-biotin) (1:1000), APOE (mAbE887-
biotin Batch 2 code 3712-6) (1:1000). After washing three times with Tris Buffered Saline with 
Tween (TBS-T), the membrane was incubated with an avidin-biotinylated secondary antibody 
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(Vectastain AB Kit, Catalogue Number PK-6100 Series) following the manufacturer’s instructions 
for 30 minutes at room temperature. The membrane was washed three times in TBS-T and 
incubated with ECL reagent for 1 minute, followed by analysis of chemiluminescent signal using 
the LI-COR digital imaging system. 
 
Figure 2.5 Schematic diagram of a dot blot (203) 
 
 
2.7.2 Enzyme-linked immunosorbent assay 
 
To further confirm there was no lipoprotein contamination in fraction 8-13, an APO Enzyme-
linked immunosorbent assay (ELISA) was applied to a representative donor plasma set. This work 
was carried out by Mabtech, Sweden. 
 
2.8 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis and Western Blot Analysis 
2.8.1 SDS-PAGE 
Discontinuous Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was 
carried out according to the method of Laemmli (1970) using the Atto Gel Electrophoresis system. 
Volumes of gel components needed for the various percentages of resolving gels are shown in 
Table 2.1. The protein concentration was measured using Nanodrop (Thermo Scientific NanoDrop 
2000 spectrophotometer). MPs were resolved through the gel at a constant current of 130 voltage 
per gel. Prestained protein ladders (Fermentas) were run alongside samples as molecular weight 
standards. 
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Table 2.1: Composition of Resolving and Stacking SDS-PAGE Gels 
 
Resolving Gel (12%) Stacking Gel (5%) 
H2O 3.3ml H2O 2.1ml 
30% Acrylamide mix 
(40:1) 
4.0ml 30% Acrylamide mix 
(40:1) 
0.5 ml 
1.5M Tris Cl pH 8.8 2.5ml 1M Tris Cl pH 6.8 0.38 ml 
10% SDS 0.1ml 10% SDS 30	µl 
10% APS 0.1ml 10% APS 30	µl 
TEMED 5µl TEMED 3	µl 
Tris Cl: Tris hydrochloride, SDS: Sodium dodecyl sulfate, APS: Ammunium persulphate, TEMED: 
Tetramethylethylenediamine 
  
2.8.3 Transfer of proteins to membrane 
The resolved proteins were transferred to a nitrocellulose membrane (Millipore) using a Trans-
Blot Electrophoretic Cell (Bio-Rad). All components were soaked in transfer buffer (25mM Tris-
HCl pH 8.0, 0.2 M Glycine, 20% methanol). The gel was placed on a layer of filter paper and 
sponge and overlaid with the nitrocellulose membranes. The second piece of filter paper was 
placed on top followed by a second sponge. The entire assembly was placed in a cassette, the 
chamber filled with transfer buffer and a constant current of 80 voltage was applied for 1 hour. 
2.8.4 Antibody blotting 
Membranes were blocked for non-specific binding by incubation in blocking buffer (TBS-T) at 
room temperature for 1 hour. The membrane was then incubated at 4°C overnight with a primary 
antibody directed against human APOA1 (1:1000 dilution). The membrane was washed 3 times 
for 10 minutes each time in TBS-T and incubated with the appropriate horseradish peroxidase 
(HRP)-linked secondary antibody for 1 hour at room temperature. Again, the membrane was 
washed three times for 10 minutes each time in TBS-T. The membrane was incubated with ECL 
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reagent for 1 minute, followed by analysis of chemiluminescent signal using the LI-COR Digital 
imaging system. 
 
2.9 Coomassie Staining of Polyacrylamide Gels 
To directly visualise the relative presence of proteins in the fractions from platelet concentrates, 
10µl of each fraction was mixed with 10µl of 2X concentrated loading buffer (7.5g of Tris-Cl, 20g 
of SDS, 1g of Bromophenol blue and 6mls of Beta-mercaptoethanol to make 500ml solution), 
boiled for 10 minutes at 95℃ and loaded on a 12% polyacrylamide gel. After the gel was run as 
described above in section 2.8.1, staining was carried out overnight using Coomassie blue (1g 
Coomassie brilliant blue in 1 litre Methanol 50% v/v Glacial Acetic acid 10% v/v H20 40%). The 
next day the gel was destained in destaining solution (Methanol 40% v/v, acetic acid 10% v/v, 
H2O 10% v/v). 
 
2.10 Cell Culture 
2.10.1 Resuscitation of frozen THP-1, HEK 293 and HeLa cell lines 
Medium was allowed to warm to 37°C before 10ml of the medium was added to a 25cm2 culture 
flask. Using cryo-gloves, an ampoule of cells (THP-1 cells, HEK293 cells and HeLa cells) was 
removed from liquid nitrogen, sprayed with ethanol, wiped dry and placed in the tissue culture 
hood. One ml of media from the culture flask was pipetted directly onto the frozen cells  and 
pipetted gently up and down to defrost cells as quickly as possible. Defrosted cells were added to 
the culture flask which was labelled and placed in the 37°C incubator. 
2.10.2 Growth of cell lines 
HeLa cells were cultured in RPMI containing a final concentration of 5ml L-glutamine, 10% (v/v) 
foetal bovine serum (FBS) and 100µg/ml penicillin/streptomycin. THP-1 cells were grown in 
RPMI containing stable 5ml L-glutamine, 10% (v/v) FBS and 100µg/ml penicillin/streptomycin. 
HEK293T cells were cultured in Dulbecco’s Modified Essential Medium (DMEM) containing 
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stable 5ml L-glutamine, 10% (v/v) FBS and 100µg/ml penicillin/streptomycin. In all cases, cells 
were maintained at 37°C in a humidified atmosphere of 5% CO2. For continuing cell culture, cells 
were seeded at 1 × 105/ml and sub-cultured two to three times a week. Cells were removed from 
the surface of the flask by incubation with 3ml trypsin-EDTA (0.05mg/ml) for 5 min at 37°C. 
Trypsin-EDTA was neutralised by the addition of 7ml of appropriate media. 
2.10.3 Cell counting and viability 
Estimation of the number of cells present in the cell suspension was carried out using a 
haemocytometer to ensure a specific number of cells was used in each well for all experiments. 
Typically, the cell pellet was resuspended in the appropriate media and 10µl of this was added to 
10µl of trypan blue. Trypan blue was used to assess the viability of the cells, as it is excluded from 
healthy cells but is taken up by non-viable cells. This mix of cells and trypan blue (10µl) was then 
added to the chamber on the haemocytometer with the number of cells present in the central 1mm2 
grid representing the number of cells in 0.1µl of the cell suspension. The number of cells/ µl was 
calculated and from this the required volume of cell suspension was seeded in each well. 
2.10.4 Differentiating THP-1 cells into macrophages 
THP-1 cells were seeded at 0.5 × 106/ml in a 24-well plate before treatment with 100ng/ml phorbol 
12-myristate 13-acetate (PMA, Sigma) for 48 hours. After 48 hours, the medium was removed and 
replaced with fresh medium without PMA. After two to three days, cells had differentiated into 
macrophages and were ready to be used for experimentation. 
 
2.11 Isolation and Visualisation of Primary Cells 
Buffy coats were obtained from the Irish Blood Transfusion Service in St James Hospital. The 
method used for isolation of monocytes was taken from Repnik et al (204). 
2.11.1 Peripheral blood mononuclear cell isolation 
Buffy coats were diluted in RPMI medium (1:2). The diluted buffy coat (25ml) was layered onto 
12.5ml of Histopaque (Histopaque 1077, Sigma-Aldrich) with a density of 1.077g/ml. The 
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suspension was centrifuged at 950g, 25°C for 15 minutes before the peripheral blood mononuclear 
cell (PBMC) layer, which interfaced between Histopaque and plasma-medium layers, was 
collected. The cells were washed three times in PBS by centrifugation at 350g, 25°C for 7 minutes      
before cells were finally resuspended in RPMI medium. 
2.11.2 Human monocyte derived macrophage isolation 
PBMCs were layered over 10ml hyperosmotic Percoll (Sigma) before centrifugation at 580g, 25°C 
for 15 minutes. The hyperosmotic Percoll solution was prepared as follows for 100ml of the 
solution: 4.85ml of Percoll mixed with 41.5 ml distilled water and 10ml of 1.6 M NaCl. The 
monocyte layer appeared between the medium layer and Percoll layer. Finally, the harvested 
monocytes were resuspended in a medium consisting of DMEM with 10% FBS and 1% 
penicillin/streptomycin before transfer to a 24 well-plate (0.5 x 106 – 1 x 106 cells/well) at 37℃ in 
a CO2 incubation. Cell viability was tested using trypan blue. The day after seeding, non-adherent 
cells were removed and medium replaced. The cell culture was maintained for at least 14 days in 
order to obtain human monocyte-derived macrophages (HMDMs). The medium was changed 
every three or four days. 
2.11.3 Visualisation of human monocyte derived primary macrophages 
The morphology of HMDMs was assessed using the Zeiss LSM 510 inverted confocal microscope. 
After HMDMs were harvested, cells were resuspended in 100µl PBS with 2% FBS and stained 
with 5µl FITC-CD11b antibody (BioLegend) for 45 minutes on ice. Cells were washed twice at 
400g, 4°C for 5 minutes each time. Finally, cells were diluted with 300µl PBS/2% FBS  and 
analysed by flow cytometry (BD Accuri C6). Unstained samples were used as negative controls in 
all measurements. 
 
2.12 Cell treatment 
THP-1 cells or HMDMs were treated with LPS (100ng/ml) alone for three hours; and/or MPs 
(0.1µg, 0.25µg, 0.5µg, 1µg) for one or four hours. The protein concentration was determined using 
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a BCA protein assay kit according to the manufacturer’s instructions (23225, ThermoFisher 
Scientific). In all cases, untreated cells were included as internal controls. 
 
2.13 Reverse Transcription-qPCR 
2.13.1 RNA extraction 
1ml of Trizol was added to each well of THP-1 cells or primary HMDMs. After cell lysis, cells 
were transferred to an RNase-free tube and incubated for 5 minutes at room temperature before 
200µl of chloroform was added for a further 5 minutes. Cells were centrifuged at 4℃ at maximum 
speed for 20 minutes in order to get phase separation. The top layer which contained the RNA was 
transferred to a clean RNase-free tube. An equal amount of isopropanol was added in order to 
precipitate the RNA. After 30 minutes incubation, samples were centrifuged at 4℃ at maximum 
speed for 20 minutes. The supernatant was removed and the RNA pellet washed with 70% ethanol. 
Finally, the RNA pellet was resuspended in 30µl of RNase-free water. The concentration and 
quality of RNA were determined by measuring absorbance at 260 and 280nm. A blank solution 
(RNase-free water) and samples (2µl) were added to the pedestal and measured. The ratio of 
absorbance at 260nm and 280nm was used to assess the purity of RNA. A ratio of 1.8-2.0 was 
accepted. 
2.13.2 Reverse transcription of RNA to cDNA 
RNA (500ng) was reverse transcribed into cDNA using iScript™ Reverse Transcription Supermix 
kit (Bio-Rad) according to manufacturer’s instructions. 
2.13.3 Quantitative PCR 
A SYBR green-based quantitative PCR kit (Quanta bio) was used according to manufacturer’s 
instructions. Reaction mixture components and PCR conditions are outlined in table 2.2 and table 
2.3 below. Primers sequences (Hs18S-r RNA and H-TNF8)used in this study are outlined in table 
2.4. 
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Table 2.2: Reaction Mixture Components for qPCR 
 
Component Volume per 30µl sample reaction (µl) 
PerfeCTa SYBR Green Fast Mix 2X 17.625 
Forward primer (10µΜ) 1.05 
Reverse primer (10µΜ) 1.05 
PCR grade water 13.7 
 
Table 2.3: Reaction Protocol for qPCR 
 
 Temperature 
 (℃) Time (min) 
Initial denaturation 95 10 
40 cycles:   
Denaturation 95 15 
Annealing and extension 60 1 
Hold 4  
 
 
Table 2.4: Primers Sequences 
 
Genes	 Primers	sequences	Hs18S-rRNA	 F:	GCTTAATTTGACTCAACACGGGA	R:	AGCTATCAATCTGTCAATCCTGC	H-TNFα	 F:	GAGGCCAAGCCCTGGTATG	R:	CGGGCCGATTGATCTCAGC	
      
2.14 Cell Line Labelling with 3-NBD-Cholesterol 
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2.14.1 Fluorescent labelling of HeLa and THP-1 cells 
Briefly, 3.5 × 105 of HeLa cells or 1.61 × 106 of THP-1 cells were seeded in a final volume of 2ml 
in 5cm2 dishes. Cells were treated with 1µg/ml of 3NBDC for 0, 1, 3, 5 or 7 hours. At each time 
point, cells were washed three times with PBS and then measured by flow cytometry (FL1 
Emission 530/30nm, Accuri C6 BD). 
2.14.2 Fluorescent labelled of extracellular vesicle treated THP-1 derived macrophages 
EVs were isolated from PFS by centrifugation at 20,000g for 60 minutes. EV pellets (760	µg) were 
then resuspended in PBS and incubated with 5µg	3NBDC for 48 hours at 4℃. After 48 hours, EVs 
were washed twice as above before flow cytometry analysis and cell treatment. THP-1 derived 
macrophages were incubated with 69µg/ml 3NBDC labelled EVs for 0, 2, 4, 8 and 16 hours. At 
each time point, the 3NBDC fluorescence intensity was tested by flow cytometry to observe 
macrophage uptake of EVs.  
2.14.3 Fluorescence intensity detection of HeLa cells 
HeLa cells were seeded in a black 96-well plate, each well containing 2 × 104 of cells. Cells were 
treated with 1µg/ml of 3NBDC for 0, 0.5, 1, 2, 5, 7, 10 or 12 hours. At each time point, the 
supernatant was removed and cells were washed 3 times with PBS. The fluorescence intensity of 
3NBDC in the medium and cells was detected by microplate spectrophotometry at a wavelength 
of 488nm for excitation and 525nm for emission. 
2.14.4 Confocal microscopy 
THP-1 differentiated macrophages and HEK293T cells were treated with 5µg/ml 3NBDC for 1 
hour, HeLa cells and human primary macrophages were treated with 1µg/ml 3NBDC for 18 hours. 
Cells were washed three times with PBS. Live cells images were acquired using the Zeiss LSM 
510 inverted confocal microscope. 
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2.15 Cholesterol Exchange Assay with 3-NBD-Cholesterol 
2.15.1 Preparation of erythrocytes 
Venous blood samples were obtained from healthy donors into EDTA vacutainers. Erythrocytes 
were separated from the plasma by centrifugation at 1,500g for 10 minutes before 1ml of fresh 
erythrocytes was removed and placed into a 15ml falcon tube. Subsequently, 5ml of flux buffer 
(150mM NaCl, 5mM NaPi, 5mM glucose) was added and samples were centrifuged three times 
for a further 5 minutes at 2,000g. 
2.15.2 Preparation of exchange plasma 
As described in section 2.14.1, plasma was removed after centrifugation at 1,500g for 10 minutes. 
Plasma was heated at 56°C for 50 minutes and then centrifuged at 15,000g for 30 minutes. Clear 
central fractions of the plasma (750µl) were removed for plasma exchange experiments. 
2.15.3 Cell labelling procedure 
Briefly, 500µl of erythrocytes was pipetted into a 1.5ml eppendorf tube and labelling solution 
(50µl of 3NBDC (1mg/ml) was added to 500µl of flux buffer) was added. Samples were incubated 
for 90 minutes on ice. After incubation, cells were washed with flux buffer as described above and 
stored on ice until the exchange experiment was carried out. 
2.15.4 Exchange assay procedure 
Exchange plasma was diluted 1:1 in flux buffer and warmed to 37°C. Briefly, 10µl of labelled 
cells was transferred to 90µl of diluted plasma in a 1.5ml eppendorf tube and incubated at 37°C. 
At each time point (0, 0.5, 1, 2, 5, 7, 10 or 12 hours), the sample was centrifuged at max speed for 
15 seconds at 4°C and 45µl of supernatant was transferred into one well of a black 96-well plate. 
The fluorescence intensity was detected by microplate spectrophotometry at a wavelength of 
488nm for excitation and 525nm for emission. 
 
 58 
2.16 Statistical Analysis 
GraphPad Prism version 7 was used for statistics calculation and plots. The D'Agostino-
Pearson test was used to measure data normality. The ROUT method (GraphPad Prism) was used 
to identify outliers. One-way ANOVA testing was applied for normal distribution data among 
three groups. The difference among the three groups was determined by one-way Kruskal-Wallis 
analysis followed by Manny-Whitney U test for data which was not normally distributed. 
Univariate correlation analysis was performed by Spearman’s rank correlation coefficients (r). 
ROC curve analysis was carried out using SPSS 25.0. p values <0.05 were considered significant. 
Multiple regression analysis was carried out using SPSS 25.0. A heat map was drawn using 
Microsoft Excel software. The sample size calculations for the human study was based on an online 
software (Power Calculator; https://www.anzmtg.org/stats/PowerCalculator/PowerCorrelation), 
which calculated sample size based on three parameters; power; correlation and significant level. 
All data is expressed as mean ±SEM or otherwise identified in the figure legends. 
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3.0 Establishing a Method for the Estimation of Cholesterol in Circulating Microparticles 
Using a Platelet Concentrate 
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3.1 Introduction 
Accurate identification and quantification of MPs has become increasingly important over recent 
times and is of great value in uncovering the biological functions of MPs. Within the last fifteen 
years, it has been shown that MPs are small cell-derived particles which are involved in various 
biological functions including pro-coagulant activity, pro-inflammatory processes and pro-
atherosclerotic processes (205, 206, 207). MPs contain a diverse array of cellular molecules 
including nucleic acids (DNA, RNA), protein and lipids (cholesterol) (9).  In recent years, the 
interest in studying MPs cargo has increased significantly due to their potential as biomarkers or 
therapeutic targets. Obtaining samples to analyse the molecular cargo of MPs in blood is a 
relatively convenient, minimally invasive procedure in a clinical setting. However, the options for 
MP isolation from sample fluids are relatively limited. To date, there is still no standard method 
for MP isolation, quantification and characterisation.  One widely used method consists of 
differential centrifugation and/or gradient purification, which often results in impure MP 
preparations which are contaminated with lipoproteins, apoptotic blebs and protein aggregates, 
including immune complexes (208).  It is generally accepted that using density-gradient 
centrifugation to isolate MPs from plasma without lipoprotein and protein contamination is 
particularly challenging, with reports suggesting that EVs (including MPs and exosomes) are often 
contaminated with HDL from human plasma as the density of HDL overlaps with the density of 
EVs (209). Furthermore, researchers have demonstrated that using density gradient approaches 
(sucrose-density gradient ultra-centrifugation in particular) may change the size of MPs and lead 
to co-isolation of HDL (210). At a recent ISEV meeting, several investigators have also reported 
that EVs isolated by sucrose-density gradient ultra-centrifugation loose some biological functions 
(63). Additionally, a further study has reported that when EVs isolated by protein organic solvent 
precipitation and are placed on THP-1cells or THP-1 cells derived macrophages, cell viability was 
reduced in vitro (57).  To this end, the combination of differential centrifugation and SEC has 
proven to be invaluable for the isolation of relatively pure MP populations, with minimally altered 
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characteristics, which therefore maintain their biological functions based on several reports (57, 
211, 212). For this reason, this was the method of choice selected for this study which set out to 
investigate the potential role which cholesterol derived from MPs (rather than HDL or LDL) may 
have in inflammatory processes in autoimmune disease.  Work presented in this chapter focused 
on the optimisation of a method to isolate and purify MPs without lipoprotein contamination. 
As >70% of circulating MPs originate from platelets, platelet concentrates (obtained from the Irish 
Blood Transfusion Service) were used for these initial optimisation and characterisation 
experiments. 
 
3.2 Aims 
● Optimise a method for MP fraction isolation from platelet concentrates 
● Investigate the size of MPs present in each fraction collected 
● Estimate the cholesterol and APO concentration of each fraction collected 
● Identify which specific fractions are cholesterol-containing and APO deficient so that these 
fractions can be selected in further studies 
3.3 Results 
This study sought to optimise a centrifugation and gradient purification protocol based on a study 
by Böing et al (63). As described in section 2.2, a sepharose (CL-2B 300 cross-linked) column 
was used to collect 35 fractions from a platelet concentrate. It is widely reported that 70-90% of 
MPs are derived from platelets in the bloodstream, therefore, the major advantage of using a 
platelet concentrate was that it was an abundant and readily available source of MPs. Particle size, 
cholesterol concentration and protein concentration of all fractions was estimated. 
3.3.1 Determination of particle size in fractions 1-35 
The size of particles present in each of the 35 MP fractions was estimated using a DLS approach. 
Values obtained were compared to published literature measurements as a way of assessing if 
particles of the correct size were being purified using this isolation method. In all cases, data 
 62 
presented is the number of particle size distribution (the relative proportion of the number of 
different particle sizes) in each fraction. The size of particles in fractions 1-14 fell between 100-
1000nm (Figure 3.1A).  The size of particles present from fraction 14 onwards were less than 
100nm in size (Figure 3.1A). As the size of MPs are 100-1000nm and the size of lipoproteins 
(HDL, LDL, IDL, VLDL) is ~5-80nm, it was possible that lipoprotein bound APO may be present 
from fractions 14 onwards. In order to investigate MPs without APO bound, fractions 1-14 was 
selected initially based on the theory of chromatography, fractions 1-7 mainly contained elution 
buffer. To confirm that fractions 1-7 did in fact contain elution buffer or contaminated material 
rather than MPs, a heat map was produced which incorporated both particle size and protein 
content of fraction (Figure 3.1B). Results demonstrated that fractions 1-7 (Figure 3.1 B yellow to 
light green colour ) contained much lower amounts of protein (0-0.012mg/mL, most likely 
background reaction as these fractions represent the column’s void volume) compared to fractions 
8-14 (0.052-1.341mg/mL) (Figure 3.1B green to red colour). In order to ensure that the fractions 
selected contained MPs and were also free from lipoprotein as much as possible, only fractions 9-
12 were used for subsequent investigations in this study.  
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Figure 3.1 Determination of microparticle size A): Fractions 1-35 were sized using dynamic 
light scattering to establish the percentage of particles present at a particular size, ranging from 
0.1-10,000nm. The size of particles in fractions 1-14 ranged from 100-1,000nm. The size of 
particles in fractions 15-35 ranged from 1-1,000nm. In all cases, number (percent) means the 
percentage of different sized particles in the fraction. B): Heatmap:protein concentration and the 
percentage of different microparticle size in fractions of 1-14. The size of fractions 1-14 range 
from 100-1000nm, the protein concentration of fraction 8-14 is much higher (0.052-1.341mg/mL) 
compared to the protein concentration of fractions 1-7 (0-0.012mg/mL). Yellows means the lowest 
value both in microparticles size and protein concentration. Red means the highest value both in 
microparticles and protein concentration. This is representative data from three independent 
experiments. 
 
3.3.2 Estimation of protein content in fractions 1-35 
To investigate the profile of proteins present in fractions isolated using centrifugation followed by 
SEC, samples from fraction 1-35 were separated by SDS-PAGE and gels were stained with 
coomassie blue. No protein was detected in fractions 1-7 (Figure 3.2A). Low levels of protein was 
detectable from fraction 8-14, with the bulk of protein being present from fraction 15 onwards 
(Figure 3.2B, C, D). The total protein content of each of the 35 fractions was also estimated at 
A280nm using the nanodrop (Figure 3.3). Results observed were in line with the SDS-PAGE 
experiments, with minimal protein (<0.01mg/ml) evident in fractions 1-7, suggesting that these 
fractions do not contain a substantial proportion of MPs and are instead mainly comprised of 
B 
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eluting buffer. These data also confirmed that protein started to appear in fraction 8, with most 
protein being present in fractions 24-28 (approx. 12mg/ml) (Figure 3.3).  Taken together, these 
results confirmed that centrifugation followed by SEC was an appropriate method to obtain protein 
containing fractions from a platelet concentrate. 
 
Figure 3.2 Presence of different proteins in fractions using SDS-PAGE and coomassie blue 
staining. Each fraction (10 µl) was mixed with 2-fold loading buffer and separated by SDS-PAGE 
before overnight staining with coomassie blue. A) Fractions 1-9, B) Fractions 10-18, C) Fractions 
19-27, D) Fractions 28-35. Molecular weight ladder weight in kDa is indicated on each gel. 
Representative gels shown from three independent experiments.  
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Figure 3.3 Protein concentration in fractions. The protein concentration of each fraction was 
determined using the nanodrop. Data shown is graphed from the average of three separate 
experiments ± SEM. 
 
 
3.3.3 Determination of the presence of Apolipoproteins in fractions 1-35 
To establish whether centrifugation followed by SEC resulted in the isolation of fractions without 
APO contamination, both ELISA and immunoblotting techniques were employed. ELISA results 
suggested no APOs were present in fractions 1-12, down to a level of sensitivity of less than 
78ng/ml (Figure 3.4A). APOB started to appear in fraction 13, peaking in fraction 22 and then 
decreased in subsequent fractions. APOA1 started to appear in fraction 15. In all other cases, the 
APO (APOD, E, H, J and M) appeared in fraction 18 and remained until fraction 29 (Figure 3.4A). 
In agreement with the ELISA data, a western blot for APOA1 further suggested there was no 
significance APOA1 contamination in fractions 10, 12 or 14 (Figure 3.4B). Taken together, these 
results indicate that fractions 1-12 are highly APO deficient. 
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Figure 3.4 Apolipoprotein concentration in fractions. (A) ELISAs were carried out to assess 
the concentration of APOA1, APOB, APOD, APOE, APOH, APOJ and APOM in fraction 1-35. 
(B) Western blot showing APOA1 concentration in plasma (positive control) and fractions 10, 12, 
14, 16, 18, 20 and 22.  
 
3.3.4 Determination of cholesterol concentration in fractions 1-35 
 
A cholesterol assay was employed in order to establish the concentration of cholesterol in each of 
the 35 fractions. Cholesterol was detected in all fractions (Figure 3.5). Lower levels were evident 
in fractions 1-8, with an increase evident until a peak cholesterol concentration was reached in 
fractions 29-35. Cholesterol was detected in fractions 1-7, which was most likely background as 
these fractions represent the column’s void volume. It must be pointed out that a platelet 
concentrate was used for these initial optimisation experiments. From a cholesterol point of a view, 
a platelet concentrate would be expected to contain a greater amount of total cholesterol when 
compared to a plasma. The platelets are in fact from five donors which have been pooled, so this 
is probably the reason for the higher cholesterol values seen here compared to subsequent assays. 
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Going forward, we applied for a more sensitive method (Amplex® Red Cholesterol Assay Kit) to 
detect cholesterol in donor plasma. 
 
Figure 3.5 Cholesterol concentration in fractions. The cholesterol concentration of each fraction 
was determined using manual colorimetric cholesterol assay. Data shown is graphed from the 
average of three separate experiments +SEM. 
 
 
3.3.5 Determination of the presence of Apolipoproteins in fractions 9-12  
Based on the above data, fractions 1-8 were excluded from further analysis as they contained little 
or no protein, and the 100-200nm material they contain, as evidenced by DLS, is most likely low 
levels of non-specific artefactual material from the isolation process. Fractions 9-12 were therefore 
selected as the fractions of interest as they contained protein and were APO deficient. In addition, 
selection of these fractions also agreed with the report by Boing et al in which a similar method 
was employed (63). In order to confirm the presence or absence of APOs in these and other 
fractions, a number of fractions were selected and immunoblotted for different APOs. As this study 
was not primarily interested in the concentration of these APOs but rather if they were present or 
not, dot blotting was employed to investigate the presence or absence of APOB, E, D, J, M and H 
(Figure 3.6). In all cases, plasma was used as a positive control. None of the APOs investigated 
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were evident in fraction 10. Although fraction 12 showed the presence of a small amount of APO 
B, E, D and J, compared to later fractions, in agreement with the ELISA data there was 
significantly less APOB, E, D, and J in fraction 12 compared to later fractions. Fraction 17 shows 
the presence of APOB, E, D, J and M while fraction 22 shows the presence of all APOs 
investigated (APOB, E, D, J, M and H) (Figure 3.6). While recognising that fraction 12 may 
contain low amounts of APO, these results confirm that fractions 9-12 are relatively APO deficient. 
      
 
Figure 3.6 Detecting the presence or absence of Apolipoproteins in fractions 10, 12, 17, and 
22. Fractions were immunoblotted for APOB, E, D, J, M and H. Plasma was used as a positive 
control in all cases. This is a representative dot blot from two independent experiments (three 
independent experiments in the case of APOB). 
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3.3.6 Determination of particle size in fractions 9-12 
DLS (Zetasizer) was employed to further investigate the size of particles in fractions 9-12 and to 
further confirm that the method of choice (centrifugation followed by SEC) was capable of 
purifying fractions containing particles of appropriate sizes which were in line with the published 
literature. Data suggested that the mean size of particles present in these four fractions was between 
~150-250nm (Figure 3.7A). A representative read out from the Zetasizer suggested that approx. 
35% of particles present in fraction 11 were around 160nm (Figure 3.7B). To further confirm 
particle size using a different technique, a representative fraction (fraction 11) was chosen for 
NTA. Results demonstrated that the mode was 144nm, meaning the main size distribution in 
fraction 11 was 144nm, with particles ranging in size from approx. 197nm to 254nm (Figure 3.7C). 
These NTA results were similar to the results obtained using DLS. Figure 3.7D depicts an image 
of particles captured by NTA. These data suggest that particles of the appropriate MP size (approx. 
150-250nm) were present in fractions 8-12. Based on equipment availability and the comparability 
of sizing results using both sizing techniques, DLS was considered suitable to routinely evaluate 
MP size for the remainder of the study. 
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Figure 3.7 Fractions 9-12 size distribution. A) The size of particles present in fractions 9-12 was 
estimated using DLS (Zetasizer). The mean size distribution was approx. 150-250nm. Data shown 
is graphed from the average of three separate experiments + SEM. B) A representative read out 
from the Zetasizer. The peak in this example suggests that approx. 35% of particles present in this 
fraction are around 160nm in size. C) Particles from fraction 11 were measured by NTA. Three 
different views were chosen to measure the size. The main size distribution was 144nm, with 
particle size distribution ranging from 197nm to 254 nm. D) An image of particles captured by 
NTA. This is a static image of different sized particles which was captured by the machine. 
      
  
3.3.7 Platelet derived (CD61+) Microparticles are present in fractions 9-12 
The most common protocol for analysis of MPs consists of differential centrifugation followed by 
flow cytometric analysis. It should be noted however that conventional flow cytometry does not 
allow size distribution determination and is poor at detecting very small particles (<200 nm), such 
as exosomes and smaller MPs. This is exacerbated by so-called 'swarm' detection of multiple small 
MPs passing through the aperture as a single event. Consequently, the detected MPs may not 
always represent the entire population. Despite these limitations, flow cytometry can enable the 
distinction of MPs of different cellular origins and the analysis of biochemical composition using 
fluorescently labelled antibodies and other probes. In this part of the study, beads (0.8µm) were 
used to set up a gate and CD61+ MPs were defined as CD61 positivity with a size ≤0.8µm (Figure 
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3.8A). Unstained cells and isotype controls were used as negative controls (Figure 3.8B-D). 
Results indicated that the percentage positivity of CD61+ MPs in fractions 9-12 was between ~60% 
- 80%, validating that the MP purification technique which was employed in this study could 
successfully isolate platelet derived MPs (Figure 3.8E-H, Figure 3.9). 
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Figure 3.8 Flow cytometry staining for CD61+ microparticles in fractions 9-12. A) Beads 
≤0.8µm was applied to set up a gate (S), (B-D). Unstained and isotype control were used as 
negative controls. (E-H) CD61+ microparticles were detected in fractions 9-12, ranging in 
percentage positivity from 60.8-75.1%. These are representative plots from three independent 
experiments. 
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Figure 3.9 The percentage positivity of CD61+ microparticles in fraction 9-12. Fractions 9-12 
contained ~ 60% - 80% of CD61+ MPs. Data shown is graphed from the average of three separate 
experiments +SEM. 
 
      
3.3.8 Estimation of cholesterol concentration in fractions 9-12 
In order to estimate the cholesterol concentration of fractions 9-12, a manual colorimetric assay 
was used. Results indicated that the cholesterol concentration in these fractions was approx. 
between 80-170 nmol/fraction (Figure 3.10).  It is worth nothing that from a cholesterol point of 
view, a platelet concentrate would be expected to contain a much higher amount of total cholesterol 
when compared to a plasma. Each platelet concentrate contains platelets which have been pooled 
together from five donors, so this is probably the reason for the much higher total cholesterol 
values observed here when compared to subsequent assays done using donor plasma (Chapter 4). 
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Figure 3.10 Determining cholesterol concentration in fractions 9-12. The cholesterol 
concentration was measured by a manual colorimetric assay in fractions 9-12. Data shown is 
graphed from the average of three separate experiments +SEM. 
 
 
3.4 Discussion 
The growing recognition of the biological role of MPs necessitates a standardisation of MP 
isolation and analysis. This is a sine qua non to reliably detect and compare MP numbers, origin 
and biological activity in health and disease. Initiatives to standardise cross-laboratory MP 
measurements have already been started by the International Society on Thrombosis and 
Haemostasis and the International Society for Extracellular Vesicles (213). To this end, in this 
study a method in which MPs can be purified from platelet-free plasma using a sepharose column 
was established. More specifically, and of unique interest to this study, cholesterol-containing MPs 
were isolated without significant HDL contamination in fractions 9-12. Based on immunoblotting 
results, there was some LDL contamination in fractions 11-12 but compared to LDL 
concentrations in platelet concentrates, the amount of LDL contamination present in these fractions 
was considerably less. Compared to other protocols for MP isolation, both differential 
centrifugation and density gradient ultra-centrifugation often show high lipoprotein contamination 
(62, 214). The use of SEC in this study has allow us to investigate a unique subset of cholesterol-
containing MPs, isolated from a lipoprotein rich environment (platelet concentrate) with little or 
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no lipoprotein contamination. The principle of SEC is based on different size separation. The 
sepharose beads pore diameter is around 75nm (63). From our results, we determined the size of 
MPs was between 150-250nm based on DLS and NTA results. Therefore the time it takes for MPs 
to pass through the column is quicker compared to HDL and LDL (<80nm). SEC appears therefore 
to be sufficient to separate MPs from HDL and LDL at >99.95% purity. 
Over recent years, methods have been developed to detect even the smallest MPs, enabling 
reliable semi-quantitative enumeration of MPs in biological fluids (215). These methods employ 
new flow cytometers equipped with a high-power lasers, high-performance photomultiplier tubes 
and wide-angle flow scatter measurements, in combination with bright fluorochromes. Since 
erythrocyte MPs and platelet MPs are easily detectable in the plasma compared with other MPs, 
and can be obtained in large quantities from transfusion products, these could be used to establish 
standardised MP measurement protocols. Combining these unambiguous protocols with a 
selective isolation method, such as FACS or immunoaffinity capture and rapidly expanding 
proteomic approaches, will provide reliable information on the mechanism(s) involved in MP 
generation and their biological function. Flow cytometry is a popular method for fast enumeration 
of MPs and determination of their cellular origin, with forward and sideward light scatter by MPs 
providing a simple way of discerning different MP populations. Considering this, we sought to 
determine CD61 positivity of MPs isolated from a platelet concentrate. Analysis of MPs by flow 
cytometry has been driven mainly by our knowledge of the proteins that are present on the plasma 
membranes of their parent cells. Inventories of MP proteomes make it possible to overcome this 
obvious restriction. In a similar fashion, progress is being made in understanding MP formation 
and pathological function through erythrocyte and platelet MP proteomics (216). It is probable that 
in the near future, proteomic approach will allow the selection of antibodies for detection of 
disease-related MP subpopulations. Thus, development of new flow cytometry analytical 
approaches is dependent on the proteomic analysis of MPs, provided they have been isolated using 
the same standardised protocols. In this study, flow cytometry was used to confirm fractions 9-12 
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contain MPs which originated from platelets. In principle, the smallest size which can be detected 
by flow cytometry is 300nm. We therefore suspect there is a swarm effect present in fraction 10-
12 analysis. 
In conclusion, this study shows MP isolation using a SEC method significantly reduces 
lipoproteins contamination. We further confirm MPs contain cholesterol, which supports other 
studies that have shown cholesterol present in MPs (24, 29, 217). This work establishes a 
methodological foundation to study the properties and biological importance of MPC. 
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4.0 Microparticle Cholesterol as a Novel Biomarker in Autoimmune Disorders 
      
      
 
 
      
 
 
 
      
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
 
4.1 Introduction 
There is a growing body of literature that recognises the important role of MPs as a biomarker in 
autoimmune disorders (218). Numerous studies have shown that circulating MP levels increase in 
RA or SLE with several papers reporting that MPs can powerfully influence processes such as 
inflammation, coagulation, thrombosis, antigen presentation and apoptosis in autoimmune 
disorders (177, 219, 220). A recent study has shown that the combination of apoptotic cell derived 
MPs and IFN-! resulted in an increase in pro-inflammatory cytokine (TNF, IL-6, IL-8) secretion 
in SLE (221). Furthermore, Nielsen et al has shown relative numbers of IG-positive MPs 
significantly increased in well-characterised SLE patients. In this study, IG-positive MPs were 
significantly associated with anti-dsDNA autoantibodies (221). Laura et al have reported MPs and 
MP immune complexes from SLE and RA patients increase adhesion molecules expression (CD54, 
CD102), chemokine production (CCL2, CCL5) and structural alterations in macrovascular and 
microvascular endothelial cells (222). Some recent studies show that circulating MPs play a 
protective role in autoimmune diseases. A paper has reported neutrophil-derived MPs can inhibit 
the release of proinflammatory factors by macrophages (IL-8, 10 and TNF!) and increase the anti-
inflammatory cytokine TGF"	in the early phase of an inflammatory response (223). EVs can also 
suppress NK and CD8+ cytotoxic functions (223). Taken together these studies suggest that MPs 
can impact the pathogenesis of  autoimmune disease and serve as biomarkers for underlying 
cellular disturbance.  Circulating or membrane cholesterol imbalance is associated with a high risk 
of developing autoimmune disorders (189, 224). The potential connection between cholesterol and 
autoimmunity was strengthened by a study by Ronda et al in which serum cholesterol efflux 
capacity was shown to be impaired in RA and SLE patients, which further increased atherosclerotic 
risk in these patients (225). Other evidence suggests that the abnormalities of monocyte-cholesterol 
interaction leads to an insufficiency of anti-infectious defence and further promotes the 
aggravation of infectious syndrome, which is a known risk factor in later RA development (226). 
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Taken together, these studies suggest that interplay between imbalanced cholesterol and abnormal 
immune cells can accelerate the inflammation process seen in autoimmune disorders, however 
there is no published study to date which has investigated the role of MPC in autoimmune disorders. 
Having already optimised a method to isolate lipoprotein deficient MPs from a platelet concentrate 
in Chapter 3, this part of the study set out to investigate the possibility of MPC as a novel biomarker 
in autoimmune diseases.     
TLRs are widely expressed on the surface of monocytes and macrophages, cells which are 
important components of the innate immune system and play a key role in host defence against 
infection through immune-inflammatory response (227). TLR4 acts as a receptor for 
lipopolysaccharide (LPS) by associating with the myeloid differentiation protein 2 (MD2) to form 
a complex to interact with LPS. The formation of the TLR4-MD2-LPS complex activates the 
adaptor molecules Myd88 or TRIF and drives pro-inflammatory signalling cascades (227). In this 
chapter, we also investigated the role of MPs on TLR4 signalling responses using MPs isolated 
from healthy control and SLE and RA patient plasma samples in an in vitro (human monocytic 
cell line: THP-1) and ex-vivo (HMDMs) model. 
 
4.2 Aims 
• Establish a reference range for MPC in healthy controls and autoimmune patients (SLE 
and RA) 
● Investigate the possibility of MPs isolated using SEC as a biomarker in autoimmune 
disease diagnosis and patient stratification. 
● Characterise inflammatory properties of MPs isolated from autoimmune disease patients 
 
4.3 Results 
4.3.1 Characterisation of microparticles isolated from healthy control plasma 
As outlined in chapter 3, the platelet concentrates used for MP isolation in the study to this point 
were from five donors pooled together and so hence we hypothesised that these MP fractions 
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contained a higher amount of total cholesterol compared to MP fractions isolated from a single 
donor plasma. In order to investigate this and to further validate the reproducibility of the isolation 
method, MP fractions were purified from 16 healthy control plasma samples. As the platelet 
concentrate was from multiple donors, it was necessary to look at individual donors to establish a 
range for MPC in a healthy control population. In each case, 1.5ml of donor PFP was loaded onto 
a sepharose column and 30 fractions were collected for characterisation studies. DLS was used for 
sizing, TEM for determining their structure and immunoblotting and ELISAs to assess and 
quantify the presence of APOs.  
Based on previous results, fractions 8-13 were selected for analysis to allow for one fraction 
either side of fractions 9-12. Results suggested that MPs in fraction 8-13 were of the correct size, 
ranging in size between 100-1000nm (Figure 4.1A). Approx. 73% of MPs present in fractions 8-
13 were between 100-300nm (Figure 4.1A black bars), ~25% of MPs between 300-500nm (Figure 
4.1A red bars), and the remaining ~2% of MPs were between 500-1000nm in size (Figure 4.1A 
blue bars). To investigate the structure of MPs isolated from donor plasma using SEC, fractions 
were visualised by TEM. Results suggested that the starting material (i.e. plasma loaded onto the 
column) contained structures of various shapes and sizes (Figure 4.1B, panel A). Fraction 2 did 
not contain any material whereas fractions 8-13 contained mostly large particles with very few 
smaller particles evident in the background (Figure 4.1B, panel C-H). The size and structure of 
particles appeared to be consistent with the presence of MPs. Later fractions 16, 18, 20, 22, 
contained MPs of various sizes and had a lot more very small particles evident in the background 
(Figure 4.1B, I-L). The smaller particle numbers were increased in the later fractions compared to 
the early fractions (fraction 8-13). It is notable that fractions 8-13 mainly contained large particles 
with few small particles, however, small particles gradually increased and large particles gradually 
decreased in the later fractions. This further confirmed that fractions 8-13 was a relatively uniform 
subset of fractions, free from a significant proportion of very small particles with a size consistent 
with that of lipoproteins and were therefore appropriate for further investigations.  
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Figure 4.1 Biophysical characterisation of healthy control microparticles. A) MP size 
distribution in fraction 8-13 as determined by DLS, data expressed as mean +SEM. Data is from 
16 healthy people. Around 73% of MPs present in fraction 8-13 were between 100-300nm (black 
bar), around 25% MPs size in 300-500nm (red bar), only around 2% MPs size fell into 500-1000nm 
(blue bar). B) Representative images from one healthy person: starting material (A), negative 
control (B), fraction 8-13 (C-H), fraction 16, 18, 20, 22 (I-L) detected by TEM. Each fraction 
contained different numbers of particles. Scale bar = 100nm. 
 
Immunoblotting and ELISAs were used to investigate the presence of APOs in various fractions. 
Dot blots showed fractions 8-13 were free from APOA1, B, E, D, H, M and J (Figure 4.2A). As 
quality control for apolipoprotein content, an APOA1 and APOB immunoblot was conducted for 
each donor plasma. An APOA1 and APOB ELISA further confirmed that fraction 8-13 are 
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expected to contain less than 0.01% lipoprotein (Figure 4.2B). A zoomed in image of ELISA 
results from fractions 10-16 (Figure 4.2B top left) clearly shows that fraction 10-13 did not contain 
significant detectable APOA1 and APOB. This further confirmed that fractions 8-13 were a subset 
of fractions that were MP-containing and lipoprotein deficient and for this reason were the 
fractions which would be used for subsequent studies in both healthy control and autoimmune 
disease patient plasma.  
 
 
      
Figure 4.2 Investigating the presence of apolipoproteins in donor plasma fractions. A)      
Immunoblot for APOA1, B, E, D, H, M and J in fraction 8-13, with plasma functioning as a 
positive control. B) APOA1 and APOB ELISAs on fractions 1-35. Fractions 8-10 were 
undetectable for APOB and fractions 8-11 were undetectable for APOA1. The limitations of 
ELISA: APOA1 is 4ng/mL and APOB is 78ng/mL. 
 
For subsequent patient studies, each donor donated only 3.5ml of whole blood which yielded 
approx. 1.5ml of PFP. In order to ensure that there was enough material for all investigations going 
forward, it was decided that 0.5ml of plasma would be loaded onto the sepharose column for 
fraction collection.  All data presented from this point applies to fractions isolated from 0.5ml of 
plasma. 
 
4.3.2 Population Demographics 
Information relating to healthy controls, SLE patients and RA patients is outlined in table 4.1 
below. Thirteen healthy controls who met the selection criteria of no hypertension or inflammation 
and had a normal lipid profile without using cholesterol-lowering medication) were recruited to 
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the study. Fourteen SLE patients were recruited to the study, of which two had no clinical 
information provided.  Fifteen RA patients were recruited based on seropositive for cyclic 
citrullinated peptide (CCP) or rheumatoid factor (RF). RA patients (57.8 ±	12.46)	 were 
significantly older than SLE patients (46.9±13.23, p<0.05) or controls (43.3 ±	11.38	,	p<0.01). 
There was no statistical difference between female/male ratios between healthy controls (10/3) and 
patient sets (SLE: 10/2, RA: 11/4) although females predominated in each group (Table 4.1, third 
row). Again this was not surprising as the autoimmune conditions being discussed here have a 
known female prevalence (228). The mean disease duration between both SLE and RA patient sets 
was also comparable, with a median value of 10 and 11 years respectively (Table 4.1, fourth row). 
Data shows that 7.7% (1/13) of healthy controls, 0% (0/14) of SLE patients and 13.3% (2/15) of 
RA patients smoked at the time of the study (Table 4.1, fifth row). The autoantibody, complement 
and medical treatment profile for the SLE patients is included in table 4.1 (middle lighter grey 
section). Laboratory results (RF, CCP, ESR, CRP and DAS28 CRP), Disease-Modifying Anti-
Rheumatic Drugs (DMARDS) and X-ray information for RA patients in outlined in table 4.1 
(lower darker grey section). 
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Table 4.1: Basic Clinical Information of Donors 
 
 Healthy Controls SLE  
Patients 
RA  
Patients 
Statistical Differences 
Number 13 14 15  
Age 
mean (SD) 
 
43.3 (11.38) 
 
 
46.9  (13.23) 
 
57.8 (12.46) 
HC versus SLE: ns 
HC versus RA: p<0.01 
SLE versus RA: p<0.05 
Gender  
(F/M) 
 
10/3 
 
10/2 
 
11/4 
 
ns 
Diseases duration, 
years median (Min - 
Max) 
 
 
N/A 
 
10  
(2 - 25) 
 
11 
(1 - 36) 
 
 
ns 
Current smokers (n)  
1 
 
0 
 
2 
 
ns 
SLE Patient Cohort 
Autoantibodies at inclusion (n) 
ANA Positive  12 
Anti-Ro 9 
Anti-La 4 
Anti-Sm 2 
Anti RNP/SM 2 
dsDNA 9 
Complement  
C3(g/L) (meanSD) 0.920.29 
C4(g/L) (mean SD) 0.1550.08 
Medicine  
Mycophenolate 3 
Prednisolone 3 
Plaquenil 6 
Azathioprine 1 
Valacylovir 1 
RA Patient Cohort 
RF (IU/ml)(median[min-max]) 124 (0-5350) 
CCP (U/ml) (median[min-max]) 219 (1-600) 
ESR (mm/hr) (median[min-max]) 14.5 (4-52) 
CRP (mg/L) (median[min-max]) 5.5 (0.5-29) 
DAS28 CRP (median[min-max]) 2.71 (1.35-4.62) 
DMARDS  
MTX 12.5mg weekly PO 2 
MTX 15 mg weekly PO 3 
MTX 20 mg weekly PO 2 
HCQ 200mg OD 2 
HCQ400mg OD 2 
SSZ 4 
Etanercept 1 
Xrays  
Erosion small joints/swollen 8 
 
N/A: Not applicable, RF: Rheumatoid factor, CCP: Cyclic Citrullinated Peptides, ESR: Erythrocyte Sedimentation Rate, 
CRP: C-reactive protein, DAS28 CRP: Disease Activity Score-28 for Rheumatoid Arthritis with CRP, DMARDS: Disease-
Modifying Anti-Rheumatic Drugs, MTX: methotrexate, HCQ: Hydroxychloroquine, SSZ: Sulfasalazine. 
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4.3.3 Microparticle size in patients and controls is not different 
MPs isolated from 0.5ml of citrate plasma from controls, SLE or RA patients using a SEC method 
has a size profile consistent with that described in the literature. The majority of MPs from each 
fraction were in the 100-300nm size range, with a significant minority in the 300-500nm range. 
Less than 10% of particles were between 500 and 1000nm. Results demonstrate that approx. 70% 
of MPs, derived from either the healthy control group or the patient groups, ranged in size from 
100-300nm (Figure 4.3, black bars). Approx. 20%-30% of MPs isolated from the healthy control 
group and both patient groups were between 300-500nm in size (Figure 4.3, red bars), with less 
than 10% of all group’s MPs falling within the 500-1000nm size range (Figure 4.3, blue bars). 
Taken together, these data suggested that there was no obvious difference in MP size in fractions 
isolated from healthy control or SLE and RA patient plasma.  
   
Figure 4.3 Microparticle size distribution in fractions 8-13 as determined by DLS. MPs from 
(A) healthy control group (n=13), (B) SLE patients (n=14) and (C) RA patients (n=15) percentage 
size distribution. Data expressed as mean +SEM. 
      
To further confirm MPs were of the correct size range, the size of MPs derived from one 
representative healthy person was measured using a different sizing technique, NTA (Figure 4.4). 
In agreement with the DLS results, MP size distribution was observed to be between 100-1000nm, 
with the majority of MPs (the peak) size range falling between 100-300nm (Figure 4.4). Fraction 
8 and fraction 13 were diluted five times before analysis and fraction 9-12 were diluted 10 times 
before analysis. Figure 4.4 shows the concentration increased from fraction 8 and reached a peak 
in fraction 11 and then decreased again. 
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Figure 4.4 Microparticle size distribution in fraction 8-13 as determined by NTA. A 
representative size distribution analysis of MPs from a healthy control. MP size distribution was 
between 100-1000nm, with the majority of MPs (the peak) size range being between 100-300nm. 
      
 
4.3.4 Investigation of the structure of microparticles in isolated fractions 
TEM was employed to confirm the presence of MPs in different fractions derived from healthy 
control or patient plasma. Some representative TEM images from healthy control and SLE patients 
are presented in figure 4.5.  Fraction 10 and fraction 11 isolated from healthy control plasma 
contained large vesicles (>100nm), which are similar in shape and size (Figure 4.5A, panel A, B), 
however, fraction 18 and fraction 20 which were also isolated from healthy control plasma contain 
numerous smaller vesicles (<100nm), which are assumed to be small exosomes and lipoproteins 
(Figure 4.5A, panel C, D). These healthy control images are consistent with the images of the same 
fractions isolated from 1.5ml of plasma which are shown in figure 4.1B. Representative images of 
fractions isolated from SLE patients are also shown in Figure 4.5. Fraction 2 (Figure 4.5A, panel 
E) did not contain any material whereas fractions 11, 12 and 13 contained particles of similar shape 
and size (100-1000nm) (Figure 4.5A, panels F-H). Later fractions 16, 18, 20 and 22 contained 
some larger particles but were mainly made up of smaller particles of similar size (5-80nm) which 
can be seen in the background (Figure 4.5A panels I-L). We assume these to be lipoprotein. 
Furthermore, dot blots confirmed that fractions 8-13 from healthy controls, SLE and RA patients 
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did not contain APOA1 and APOB (Figure 4.5B). Results therefore confirmed that fractions 8-13 
were relatively uniform in structure, contained particles of similar shape and size and were 
lipoprotein deficient.  
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Figure 4.5 Determination of structure and apolipoprotein content in representative fractions. 
A) Representative TEM images of fraction 10, 11, 18 and 20 from a healthy control (A-D). 
Representative TEM images of fractions 2, 11, 12, 13, 16, 18, 20, 22 from two SLE patients (E-
L). Scale bar =100nm. B) Immunoblot for APOA1 and APOB in fractions 8-13 from healthy 
control (HC), SLE and RA patients, with plasma functioning as a positive control. This is a 
representative immunblot. All samples were examined by dot blot. 
 
4.3.5 Determination of the cell of origin of microparticles in fractions 8-13 
Flow cytometry was used to investigate the cell of origin of MPs present in fractions 8-13 isolated 
from healthy control, SLE patient and RA patient plasma. In all cases, fractions were stained with 
platelet markers (CD61+/CD42b+), endothelial cell markers (CD31+CD42b-) and a leucocyte 
marker (CD45+) in order to establish the MP cell of origin. The numbers of MPs originating from 
different cells in healthy controls and patients groups was investigated. Results showed that there 
was no significant difference in the amount of resting platelet derived (CD42b+) MPs observed 
between each group (Figure 4.6A). There was however a significant difference in the amount of 
platelet derived (CD61+) MPs in SLE (p<0.001) and RA patients (p<0.01) compared to healthy 
controls, with both patient groups showing an increased amount (Figure 4.6B).  Neither SLE or 
RA patients contained significantly more leucocyte (CD45+) derived MPs compared to healthy 
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controls, although RA patients were shown to have significantly more (p<0.05) of this type of MP 
compared to SLE patients (Figure 4.6C).  Both SLE and RA patient groups contained more 
endothelial cell (CD31+CD42b-) derived MPs compared to healthy controls, with p values of 
p<0.05 and p<0.001 respectively (Figure 4.6D). Our results are consistent with several studies 
which have reported that there is increased levels of active platelet (CD61+) derived and 
endothelial (CD31+CD42b-) derived MPs in autoimmune diseases patients (166, 229, 230). 
  
 
Figure 4.6 Characterisation of circulating microparticles from healthy control, SLE and RA. 
A) The number of general platelets derived MPs (CD42b+). B) The number of active platelets 
derived MPs (CD61+). C) The number of leucocyte derived MPs (CD45+). D) The number of 
endothelial cell dervied MPs (CD31+ CD42b-) in healthy control, SLE patients group and RA 
patients group. Each data point presents an individual participant, and the median shown as a black 
line. All comparisons not specified in the figures were not significant (ns). All of data are based 
on 13 healthy controls, 14 SLE patients and 15 RA patients. 
 
4.3.6 Investigation of the lipid profile of donors and cholesterol content of microparticles in 
fractions 8-13 
Total cholesterol and triglyceride levels were estimated in both healthy controls and patients 
subsets. D'Agostino-Pearson testing was used to measure data normality. Total cholesterol values 
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in the healthy control and patient groups were all within the normal range. One-way ANOVA 
testing indicated that there was no significant difference in total plasma cholesterol levels between 
the three groups (Figure 4.7A). The rest of the data presented in figure 4.7 (B-D) was found to not 
be normally distributed. Kruskal-Wallis testing revealed that there was no significant difference in 
triglyceride concentration among groups (Figure 4.7B). The cholesterol content of MPs from 
fractions 8-13 was estimated. RA patients had significantly greater cholesterol content in MP 
compared to healthy controls and SLE patients (p<0.01), (Figure 4.7C). There was no difference 
in the MPC content between healthy controls and SLE patients. Outlier identification analysis 
(ROUT method) was applied to discover any potential outliers within the three groups. One outlier 
was identified in the healthy control group (Figure 4.7C, red dot). In all cases, the outlier was 
excluded in statistical analysis. Statistical analysis confirmed that RA patients had significantly 
more (p<0.01) MPC as a percentage of total plasma cholesterol when compared to both healthy 
controls and SLE patients (Figure 4.7D). There was no difference in MPC expressed as a 
percentage of total plasma cholesterol values between healthy controls and SLE patients. Although 
MPC accounted for approximate 1.5% of total cholesterol in RA patients, that was almost three 
times higher than the percentage in healthy controls (approx.0.5%) and SLE patients (approx. 
0.5%). Again, the ROUT method identified one outlier in the healthy control group (Figure 4.7D, 
red dot).  
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Figure 4.7 Autoimmune patients have increased microparticle cholesterol compared to 
healthy controls. A) Total cholesterol concentration in healthy control and patient groups. Data 
was expressed as mean ±SEM. B) Triglyceride concentration in healthy control and patient groups. 
Data was expressed as median with black dots. C) Microparticle (MP) cholesterol in healthy 
control and patient groups, Data was expressed as median with black dots. Red dot symbolises 
outlier. D) MP cholesterol expressed as a percentage of total plasma cholesterol in healthy control 
and patient groups. Data was expressed as median with black dots. Red dot symbolises outlier.  In 
all cases, these data are based on 13 healthy controls, 14 SLE patients and 15 RA patients. 
 
4.3.7 Investigation of potential correlations between microparticle, microparticles 
cholesterol and clinical parameters 
As MPs can reflect the inflammatory state observed in SLE or RA patients (231), we hypothesised 
that MPs derived from different cells of origin could be associated with some clinical inflammatory 
indexes, such as C3, C4, CRP, CCP and RF. Spearman correlation was used to investigate the 
association between MPs and clinical parameters. In the case of RA patients, CRP levels were 
shown to positively correlate with the number of active platelet derived (CD61+) MPs present 
(Figure 4.8A, p=0.052, R=0.51).  CCP levels were shown to positively correlate with the number 
of leucocyte derived (CD45+) MPs present (Figure 4.8B, p=0.048, R=0.52), and RF levels were 
shown to positively correlate with the number of endothelial derived (CD31+CD42b-) MPs present 
(Figure 4.8C, p=0.0040, R=0.73). This suggests that MPs derived from RA patients are related to 
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the clinical parameters from RA diseases, which indicates the inflammatory status of diseases. 
Furthermore, There is no correlation between MPC derived from RA patients and any clinical 
parameter investigated (Figure 4.9A-E). Likewise, there is no correlation between MPC and total 
cholesterol in RA patients (Figure 4.9F)
 In the case of SLE patients, serum C3 levels were shown to negatively correlate with the number 
of endothelial derived (CD31+CD42b-) MPs present (Figure 4.8D, p=0.038, R=-0.6). Generally, 
the typical pattern in active SLE patients is low C3 levels, with C3 levels rising after treatment. In 
our study, only two SLE patients were active, with the rest being inactive. This is the reason that 
C3 levels are in the normal range (0.8-1.6g/L). However, CD31+CD42b- MPs increased in inactive 
SLE patients and was negatively correlated with C3 levels, which suggests CD31+CD42b- MPs is 
a more useful biomarker to diagnose inactive SLE patients than C3 levels. 
  
 
 
Figure 4.8 Correlations between microparticles derived from different cell types and clinical 
parameters in patient groups. A) Correlation between active platelet derived (CD61+) MPs and 
CRP level in RA patients B) Correlation between leucocyte derived (CD45+) MPs and CCP level 
in RA patients C) Correlation between endothelial cell derived (CD31+CD42b-) MPs and RF level. 
Log10 = logarithm (base 10) in RA patients. D) Correlation between endothelial cell derived 
(CD31+CD42b-) MPs and serum C3 level in SLE patients. 
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Figure 4.9 Correlations between microparticle cholesterol (MPC) and clinical parameters in 
RA patients. A) Correlation between MPC and CCP levels. B) Correlation between MPC and 
CRP levels. C) Correlation between MPC and RF levels. D) Correlation between MPC and ESR 
levels. E) Correlation between MPC and DAS28 CRP score. F) Correlation between MPC and 
total cholesterol. 
 
 
4.3.8 Using microparticle cell of origin numbers and microparticle cholesterol levels to 
define diagnostic parameters in healthy control and patient groups 
 
Receiver Operating Characteristic (ROC) analysis was performed to identify the cut-off values for 
CD61+ MPs, CD31+CD42b- MPs, CD45+ MPs and MPC in order to distinguish each donor group 
from one another. The area under the ROC curve (AUC) was used to estimate the accuracy of the 
diagnostic test for the discrimination between RA patients, SLE patients and healthy controls. 
AUC values range from 0 to 1. Generally, an AUC of 0.5 suggests that patients with or without 
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the disease cannot be classified by this biomarker, an AUC of 0.7 to 0.8 is considered acceptable, 
an AUC of 0.8 to 0.9 is considered excellent and more than 0.9 is considered outstanding. The 
main limitation of AUC does not account for different misclassification which arise from false-
negative and false-positive diagnoses. Table 4.2 shows AUC, 95% confidence interval (CI), cut 
off, sensitivity, specificity and p-value for all parameters tested. 
AUC values (>0.7) and sensitivity and specificity values from table 4.2 were used to assess 
the potential diagnostic value of different parameters.  Analysis of healthy controls versus RA 
patients demonstrated AUC values for CD31+CD42b- MP number, CD61+ MP number and MPC 
amount were more than 0.8, which suggests that these three biomarkers were capable of classifying 
patients with or without RA diseases (Figure 4.9A). Analysis of healthy controls versus SLE 
patients suggested that CD31+CD42b- MP number and CD61+ MP number were useful biomarkers 
in distinguishing patients with or without SLE (Figure 4.9B). CD61+ MPs numbers had a higher 
AUC value (0.881) than CD31+CD42b- MP number (0.756), which suggests CD61+ MP number 
was more accurate at diagnosing SLE when compared to CD31+CD42b- MP number (Table 4.2, 
Figure 4.9B). CD45+ MP number and MPC amount were both considered to be useful biomarkers 
to distinguish SLE from RA based on AUC values >0.7 (Figure 4.9C). Furthermore, results 
suggested that MPC, CD31+CD42b- MP number or CD61+ MP number was capable of classifying 
patients with or without autoimmune diseases, however, CD31+CD42b- MP number or CD61+ MP 
number was not able to distinguish SLE from RA disease, with only MPC showing promise in this 
regard. This suggests MPC to be a promising biomarker to diagnosis SLE and RA patients, who 
often present with overlapping symptoms. 
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Table 4.2: ROC Curve Analysis to Define Diagnostic Parameters in Healthy Control and 
Patients Groups 
 
Biomarker AUC 95% CI Cut off Sens. Spec. p 
value 
Healthy Controls and RA Patients 
CD31+CD42b-MPs 0.861 0.698-1 4.84 
counts/μl 
1 0.750 0.002 
CD61+ MPs 0.872 0.722-1 47.33 
counts/μl 
0.867 0.833 0.001 
CD45+ MPs 0.661 0.453-0.869 23.53 
counts/μl 
0.600 0.670 0.157 
CD42b+ MPs 0.533 0.311-0.756 194.54 
counts/μl 
0.267 1 0.770 
MPC 0.828 0.655-1 0.015 
μmol 
0.800 0.917 0.004 
Healthy Controls and SLE Patients 
CD31+CD42b- MPs 0.756 0.554-0.795 6.68 
counts/μl 
0.786 0.833 0.027 
CD61+MPs 0.881 0.735-1 33.97 
counts/μl 
1 0.750 0.001 
CD45+MPs 0.387 0.156-0.618 4.89 
counts/μl 
1 0.167 0.328 
CD42b+MPs 0.583 0.345-0.822 65.08 
counts/μl 
0.714 0.750 0.471 
MPC 0.565 0.336-0.795 0.012 
μmol 
0.500 0.833 0.572 
SLE Patients and RA Patients 
CD31+CD42b- MPs 0.560 0.340-0.779 12.96 
counts/μl 
0.467 0.786 0.585 
CD61+ MPs 0.438 0.224-0.652 48.08 
counts/μl 
0.867 0.214 0.570 
CD45+ MPs 0.771 0.593-0.950 17.42 
counts/μl 
0.8 0.714 0.013 
CD42b+ MPs 0.514 0.289-0.739 181.94 
counts/μl 
0.267 1 0.896 
MPC 0.786 0.611-0.961 0.019 
μmol 
0.733 0.857 0.009 
CI: Confidence interval, Sens: Sensitivity, Spec: Specificity, AUC: Area under the curve; MPC: 
Microparticle cholesterol 
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Figure 4.10 ROC curve analysis in healthy control and patient groups. A): ROC curve analysis 
results of CD61+ MPs (purple line), CD31+ CD42b- MPs (yellow line) and microparticle 
cholesterol (MPC) (red line) in healthy controls versus RA patients. B): ROC curve analysis results 
of CD61+ MPs (purple line) and CD31+ CD42b-  MPs (yellow line) in healthy controls versus SLE 
patients. C) ROC curve analysis in CD45+ MPs (blue line) and MPC (red line) in SLE versus RA 
patients.  
 
4.3.9 Microparticles attenuate TNFα and TLR4 expression in LPS-induced inflammation 
Preliminary experiments have been carried out to explore the role of MPs in inflammatory 
responses. MPs isolated from healthy controls, and SLE and RA patient subsets were used to treat 
cells (THP-1 cells, HMDMs) and TNFα and TLR4 expression was measured. The availability of 
SLE and RA patients in an “active” disease status often hampers these types of investigations. 
Initial experimental work in this area was carried out in collaboration with Prof. Caroline Jefferies 
at her laboratory in Cedars-Sinai Hospital, where plasma was available from SLE patients with 
active and inactive disease. To investigate the effect of MPs on LPS induced responses, cells were 
pre-treated with MPs for 1 hour and then treated with LPS for a further 3 hours. Some optimisation 
experiments in which cells were treated with MPs for 3 hours rather than 1 hour showed similar 
results so as a starting point a 1 hour treatment time was selected. However, further experiments 
are needed to investigate the effect of MPs on TLR4 and TNFα responses over a longer MP 
pretreatment time course. Three hour LPS treatment is a standard treatment length to see both 
surface protein changes and gene expression of both early and later acting inflammatory genes 
such as TNFα. A longer LPS treatment time of 24 hours will be needed in future experiments when 
cytokine release is being investigated.  
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Results show that treatment of THP-1 cells with a high concentration (13µg total protein) of MPs 
for one hour, followed by LPS stimulation for three hours, lead to alterations in LPS induced TNFα 
mRNA levels (Figure 4.10). Notable differences were observed in cells which were pretreated with 
MPs derived from an active SLE patient almost completely obliterating the LPS induced 
expression of TNFα mRNA compared to MPs derived from both healthy controls and an inactive 
SLE patient. Although these treatment conditions may be considered supraphysiological, these 
initial data provided insight and direction into the design of subsequent experiments and verified 
the importance of having both disease active and inactive donors.  
 
Figure 4.11 Pretreatment of THP-1 cells with microparticles from active SLE patients 
downregulates LPS induced TNFα mRNA expression. TNFα mRNA levels were measured in 
THP-1 cells which had been pretreated with MPs from 2 healthy controls (HC), 1 inactive or 1 
active SLE patients for 1 hour with/without LPS treatment for a further 3 hours.  Data is expressed 
as mean +SEM. 					           
      
In order to mimic normal pathophysiological levels, a lower concentration of MPs was used for 
subsequent cell treatment experiments. As normal human plasma contains 2 to 4µg/ml of MP 
protein, THP-1 cells were pretreated with 1µg of MPs (concentration 2µg/ml) for subsequent 
experiments. As TNFa is produced downstream of TLR signaling, therefore the effects of MPs 
effect on TLR4 surface expression was assessed by flow cytometry. Results show that pretreatment 
with MPs derived from healthy controls did not reduce basal or LPS induced TLR4 expression 
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whereas this was reduced after pretreatment with MPs derived from both active SLE and RA 
patients (Figure 4.12). Although these results are preliminary, interestingly MPs from the inactive 
RA patient had no downregulating effect on LPS induced TLR4 expression, again suggesting the 
differences from a functional point of view between MPs produced in active versus inactive 
disease (Figure 4.12, red dot). 
     
 
 
Figure 4.12 Pre-treatment of THP-1 cells with microparticles from autoimmune patients 
downregulates LPS induced TLR4 expression. THP-1 cells were pre-treated with 1µg of 
microparticles (2µg/ml) derived from two healthy controls, two active SLE patients, one active 
RA patient and one inactive RA patient (red dot) for 1 hour followed by +/- LPS treatment for a 
further 3 hours. TLR4 protein expression was analysed by flow cytometry. All data was normalised 
to cells which had been treated with LPS only for 3 hours. 
      
To further investigate the preliminary data acquired from the THP-1 cell line above, experiments 
were repeated in HMDM primary cells. In all cases, HMDMs were isolated from buffy coats 
obtained from the Irish Blood Transfusion Service. A representative image of HMDMs isolated 
from a buffy coat is shown in figure 4.13A. Once purified, HMDM CD11b (macrophage marker) 
expression was assessed by flow cytometry (Figure 4.13, C).  
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Figure 4.13 Characterisation of human monocytes derived macrophages. A) A representative 
image of HMDMs isolated from a buffy coat. Scale Bar=30µm. B) Gates were set up on the flow 
cytometer to exclude debris and dead cells. C) HMDMs express CD11b (Red line). FSC: forward 
scatter. SSC: side scatter.  
 
 
Treatment of HMDMs was according to an identical protocol to that described above with the 
exception of a lower amount (0.1µg) of MPs being used in these experiments in order to investigate 
how potent the MPs were. Treatment with MPs from two active RA patients lead to a 50% 
reduction in surface expression of TLR4 as judged by flow cytometry, under both basal and LPS 
stimulated conditions (Figure 4.14A). This reduction in LPS induced TLR4 expression was not 
observed post treatment with MPs from the inactive RA patient (Figure 4.14A, red dot). 
Assessment of TNFα mRNA levels under similar experimental conditions revealed a MP 
dependent reduction in LPS induced TNFα mRNA expression. MPs from both SLE and RA had 
similar impacts on mRNA levels, but there was no impact under basal conditions (Figure 4.14B). 
This is most likely due to the low basal expression of TLR4 and therefore the limited scope to 
observe a reduction in gene expression. Although these results are provisional, they do uncover a 
novel mechanism of immunomodulation which may be of importance under in vivo conditions. 
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Figure 4.14 Microparticles from autoimmune patients reduce basal and LPS induced TLR4 
and TNFα expression. In all cases, HMDMs were pretreated with 0.1µg of MPs from either three 
healthy controls, three RA patients (two active and one inactive (red spot)) or two active SLE 
patients for 1 hour followed by LPS treatment for 3 hours. A). TLR4 protein expression was 
measured by flow cytometry. Data was expressed as mean ±SEM. All data was normalised to cells 
which had been treated with only LPS for 3 hours. B) TNFα mRNA levels were measured by q-
PCR. Data expressed as mean ±SEM. 
 
   
4.4 Discussion 
Consistent with similar reports, in this study, MPs originating from platelets (CD61+) and 
endothelial cells (CD31+CD42b-) were significantly higher in SLE and RA patients compared to 
healthy controls (166, 229, 230). Furthermore, this study provides new insights into MPC levels 
in SLE and RA and demonstrated for the first time that MPC in RA patients is significantly 
increased compared to healthy controls and SLE patients. Above all, our results demonstrated how 
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an increased level of MPC could provide a valuable platform for distinguishing SLE and RA 
disease and holds promise as a new biomarker. 
Our findings around increased CD61+MPs and CD31+CD42b-MPs in both patient groups 
compared to healthy controls, with no difference in CD45+MP or  CD42b+MP levels is in line with 
other studies  (166, 229, 230, 231). Our results demonstrate that RA patients had an increased 
number of CD45+ MPs compared to the SLE patient group. One reason for this could be related to 
disease status, as the SLE group contained only two patients with active disease (SLEDAI score>6). 
Our results showed the level of MPC to be significantly increased in RA patients compared 
to both SLE patients and healthy controls. Uzma et al have reported that dyslipidaemia is observed 
in active RA disease, with patients often having low cholesterol levels yet high CVD risk (232). 
The paradoxical lipid changes observed in RA are not fully understood. Due to the nature of the 
disease, RA patients were significantly older than SLE patients and controls but we found no 
correlation between MPC and age. Furthermore, multiple regression analysis was applied to 
evaluate clinical and biochemical variables age, gender, smoking, total cholesterol, triglycerides, 
CRP, CCP, RF, ESR, DAS28 as independent variables in regression models of the dependent 
variable MPC. Results showed MPC to be an independent risk factor. This is the first study to our 
knowledge to demonstrate cholesterol accumulation in MPs derived from RA patients, with MPC 
derived from RA patients showing potential as a novel biomarker to diagnose RA disease. 
It is widely accepted that MPs can function as biomarkers in autoimmunity, with increased 
levels being observed in many diseases (23, 218, 231, 233). However, these studies have focused 
on using MPs to diagnose autoimmunity in general, rather than classifying autoimmune diseases. 
In this study, CD61+MPs and CD31+CD42b-MPs could separate autoimmune patients and healthy 
controls, while MPC could further distinguish RA from SLE. Several studies report MPs derived 
from autoimmune diseases patients as having pro-inflammatory effects (234, 235). Recently, one 
study has reported platelet-derived MPs have anti-inflammatory effects in human plasmacytoid 
dendritic cells. Platelet-derived MPs decreased TNFa and IL-8 secretion after platelet-derived 
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MPs uptake by human plasmacytoid dendritic cells (236).  Another study further reports that EVs 
derived from endothelial cells can reduce proinflammatory responses by inhibiting NF-κB 
signalling pathways (237). The precise mechanism of action is still unclear. The authors suggest 
that proteins or lipids contained within the EVs contribute to their anti-inflammatory and 
immunomodulatory effects (237). Another study by  Čebatariūnienė et al. reports that EVs purified 
from periodontal ligament stem cells can suppress LPS-induced NF-κΒ signalling pathways (238). 
Our preliminary results in this study suggest that the anti-inflammatory effects of MPs may be 
involved in TLR4 - NF-κB -TNFα signalling pathways.  
In conclusion, in this pilot study, we establish a candidate reference range of MPC 
(0.003µmol -0.03µmol) in a representative healthy control population. Furthermore, we report 
striking differences in MPC levels among patients and age matched controls, suggesting its 
potential as a novel biomarker and usefulness in patient stratification. Despite these promising 
results, further work is required to fully elucidate MPs exact mechanism of action in inflammatory 
responses.  
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5.0 3-Hexanoyl-NBD-cholesterol is a versatile membrane cholesterol tracer 
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5.1 Introduction 
Cholesterol is a fundamental component of the cell membrane and plays an important part in 
maintaining cell membrane integrity and fluidity (80). Cholesterol is transported in plasma as a 
component of lipoproteins due to very low water solubility (110). The basic cholesterol structure 
and biosynthesis were described in chapter 1 (section 1.3). Cholesterol is not homogenously 
distributed in mammalian cells. Depending on cell types, it is widely accepted that the cell 
membrane contains most of the cellular cholesterol (110). The endoplasmic reticulum is the 
organelle which synthesises cholesterol but in fact contains very low cholesterol as the cholesterol 
is rapidly transferred from the endoplasmic reticulum to other organelles once synthesised (110). 
Excess cholesterol is known to have cytotoxic effects in cells, therefore, the exact amount of 
cholesterol the cells need for physiological functions needs to be very tightly regulated (110). Cells 
are adept at removing excess cholesterol in several ways which involve the liver X receptor family, 
ATP binding cassette transporters (ABCA1, ABCG1) and other binding proteins (110, 239). 
Therefore, robust and efficient sensors and tracers of cholesterol are needed to support research 
into different aspects of cholesterol behaviour, including localisation, uptake, diffusion and efflux 
(110, 240) Previous studies have shown that fluorescent cholesterol analogues could be 
investigated in lipid trafficking as cholesterol is not fluorescent (107, 241). Fluorescent analogs of 
cholesterol can be divided into intrinsically fluorescence sterols and extrinsic or tagged sterol 
probes (110). Intrinsically fluorescent cholesterol analogs include dehydroergosterol, 
cholestatrienol, cholestatrienol esters and cholesteryl parinaric acid as lipoprotein probes.  
Extrinsic cholesterol analogs include boradiaza-indacene-tagged cholesterol, 6-Dansyl-
cholesterol, NBD-tagged cholesterol and pyrene-tagged cholesterol (110). The advantages and 
disadvantages of commonly used fluorescence sterol probes as described in Table 5.1 (110).   
In this project, we are more interested in studying NBD-tagged cholesterol analogy. In 
most research 22NDBC has been used as the cholesterol probe (108, 109), however, a recent study 
has suggested that insertion of the fluorescence tag of 22NBDC in the membrane can change the 
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ability of cholesterol to move (111). The rate of 22NBDC exchange between the cells and the 
acceptor is much faster when compared to the normal cholesterol exchange rate. The chemical 
structure of different NBD-cholesterol is shown in Figure 5.1. As can be seen in this figure, the 
fluorescent tag (Figure 5.1, red box) of 22NBDC and 25NBDC are inserted into the membrane 
bilayer.  By contrast, the fluorescence tag of 3NBDC is attached to carbon 3 via a C6 spacer, at 
the hydrophilic end of cholesterol (Figure 5.1, red box), which is outside the membrane bilayer 
(110, 111, 112). This structure would thus be anticipated to more appropriately mirror the normal 
orientation of cholesterol in the membrane and recapitulated the interactions with other membrane 
components, such as phospholipids.  Traditionally, radioisotope-labelled cholesterol is used as a 
cholesterol tracer for metabolic studies in cells and whole organisms, as well as to determine the 
exchange rate between cells and acceptors (242, 243). However, this method is not feasible in 
every lab and there are safety and regulatory issues with the use of radioactivity. In many fields, 
radioactive molecules have been replaced with fluorescent tracer molecules, which are easier to 
use and amenable to high throughput screening platforms. Although there are a number of 
fluorescent cholesterol analogs (labelled on the side chain) in current use, they suffer from different 
biophysical and technical limitations. Thus this study aims to explore the use of a recently 
described fluorescent analog, 3NBDC, as a biochemical tool to track cholesterol dynamics, with a 
particular interest in evaluating its use in studies on MPC. 
      
 
Figure 5.1 Chemical structure of 3-NBD-Cholesterol, 22-NBD-Cholesterol and 25-NBD-
Cholesterol.The fluorescence tag NBD group is shown in the red box. 
 115 
Table 5.1 Advantages and disadvantages of commonly used fluorescent cholesterol probes 
 
Cholesterol probe Advantages Disadvantages 
Fluorophore bound 
to bacterial toxins 
as perifringolysin O 
Used to assess threshold concentrations 
of cholesterol in models & cell 
membranes.  
Partly useful for super-resolution 
microscopy. 
Cannot track inter-organelle transport nor 
sterol diffusion, do not bind esters. 
Trafficking studies only infixed cells, unless 
genetically encoded. 
Filipin Reliable quantitative measure of 
cholesterol. 
Partition into lo phase in model 
membranes. 
Useful for assessing cholesterol content 
in tissue samples. 
Cannot track inter-organelle transport or be 
used in living cells. Do not bind esters. 
Requires UV optics. 
Cross-reactivity to gangliosides. 
 
Dehydroergosterol Closest analogue to ergosterol followed 
by cholesterol; gets bound and 
transferred by sterol transfers proteins. 
Induces and partitions into lo phase in 
model membranes 
Can replace cholesterol or ergosterol in 
sterol-auxotroph organisms. 
Low brightness, requires UV optics, 
bleached easily, limited substrate for acyl-
coenzyme A acyl transferase 1 in 
mammalian cells. 
Cholestatrienol Closest analogue of cholesterol; gets 
bound and transferred by sterol transfers 
proteins. 
Partitions into lo phase in model 
membranes & orders phospholipids 
almost as good as cholesterol. 
Low brightness, requires UV optics, 
bleached easily. 
Parinaric acid 
cholesteryl esters 
Does not alter sterol structure. Cannot track cholesterol after hydrolysis. 
Requires UV optics. 
Broadiaza-indacene 
cholesterol 
High brightness and good photostability. 
Partitions into lo phase in model 
membranes. 
Ease of use in conventional fluorescence 
microscopy. 
Partly useful for dynamic super-
resolution microscopy. 
High affinity to lipid droplets, thereby 
partial miss-targeting in cells. 
No ordering of fatty acyl chains in model 
membranes. 
Usability in yeast is questionable. 
Not substrate for all known sterol transfers 
proteins. 
Dansyl-cholesterol High brightness, small molecule. 
Ease of use in conventional fluorescence 
microscopy. 
Partitions into ld phase in model 
membranes. 
Prone to bleaching. 
Not substrate for all known sterol transfers 
proteins. 
Pyrene-cholesterol Forms excimers with potential use in 
membrane sterol aggregation. 
No esterification. 
Requires UV optics. 
Partition preference and binding to sterol 
transfers proteins not known. 
Dye-linked 
polyethylene 
glycol-cholesterol 
Very photostable. 
Very useful for dynamic super-resolution 
microscopy. 
No flip-flop & no non-vesicular transport. 
No metabolism. 
Click chemistry 
substrates 
Mimic cholesterol very well before click 
reaction, many possible analytical 
enhancers to optimize fluorescence. 
Useful for super-resolution microscopy. 
Cannot be used in living cells. 
Behaviour of fluorescent analogue after 
click reaction is poorly characterized. 
22/25-NBD-
cholesterol 
Easily absorbed from media. 
Ease of use in conventional fluorescence 
microscopy. 
Prone to bleaching orientation in membranes 
opposite to cholesterol. 
Partitions into ld phase in model 
membranes. 
Not substrate for all known sterol transfers 
proteins.  
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5.2 Aims 
● Confirm that 3NBDC replicates the biophysical behaviour of cholesterol using an 
intramembrane exchange model 
● Characterise the uptake of 3NBDC in cell systems 
● Evaluate the potential of 3NBDC to label and track MP uptake under in vitro conditions 
 
5.3 Results  
5.3.1 Cholesterol exchange between erythrocytes and autologous plasma 
     Previous research has established that radioisotope-labelled cholesterol may be used to study 
the rate of cholesterol exchange between donor erythrocytes and acceptor plasma (243, 244). To 
assess if 3NBDC could replace radioisotope cholesterol based methods, we carried out studies of 
the 3NBDC exchange rate between erythrocytes and autologous plasma under similar conditions 
to that used for radiolabelled cholesterol. This cell model was used to ensure that there was no 
possible metabolism of cholesterol in the experimental system and ensure that the results were 
based on the partition of cholesterol between the donor cellular membrane and the acceptor 
lipoprotein.  Cholesterol efflux from labelled erythrocytes to plasma lipoproteins led to a time 
dependent and the equilibration of the label between the two different compartments (erythrocytes 
membrane and plasma lipoprotein), as assessed by the appearance of the fluorescent label (Figure 
5.2). Similar to previous studies using radiolabelled cholesterol, an initial fast phase was followed 
by a plateau after 7 hours (245, 246). These data are consistent with the expected behaviour of 
radiolabelled cholesterol under similar conditions (247). 
 
 117 
      
Figure 5.2 3-NBD-cholesterol exchange between erythrocytes and plasma. The exchange rate 
was measured by increasing the 3NBDC fluorescence intensity of unlabelled plasma. The rate of 
exchange increased dramatically in the first half an hour and reached a plateau at 7 hours. Data are 
expressed as mean ±SD. The data is based on three healthy donors and four independent 
experiments. This experiment has been carried out by multiple experimenters with similar results 
in every case. 
      
5.3.2 Uptake of 3-NBD-Cholesterol using in vitro cell systems  
To confirm 3NBDC uptake by different cell lines, HeLa cells were stained with 3NBDC (1µg/ml) 
for different durations. Confocal microscopy and flow cytometry were then used to characterise 
uptake by HeLa cells. The ability to use flow cytometry to track the uptake of 3NBDC is an 
advantage of this sensor.  Data from flow cytometry revealed a time-dependent uptake by HeLa 
cells (Figure 5.3A). After 7 hours, almost 80% of HeLa cells were labelled to some extent by 
3NBDC. Figure 5.3B shows a representative flow data of 3NBDC uptake in HeLa cells after five 
hours incubation. In parallel experiments, labelling of HeLa cells with 3NBDC was evaluated by 
live cell microscopy. Again, time-dependent cell labelling is evident, with initial scattered labelling 
(Figure 5.3D, E) followed by widespread labelling of cells after 18 hours of incubation (Figure 
5.3F). Labelling of cells in this case is expected to proceed by at least two mechanisms - i) direct 
update of 3NBDC from the bulk media by HeLa cell membranes and ii) labelling of lipoproteins 
present in the medium followed by uptake of labelled lipoproteins by receptor mediated processes. 
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Similar time-dependent uptake results were obtained from THP-1 cells (results not shown). Taken 
together, results from live cell imaging and flow cytometry further support the contention that 
3NBDC is a viable cholesterol tracer.  
 
 
          
 
 
 
Figure 5.3 HeLa cell uptake of 3-NBD-Cholesterol. A) HeLa cells were incubated with 1µg /ml 
of 3-NBD-Cholesterol (3NBDC) for 1, 3, 5 and 7 hours and analysed by flow cytometry. Cell 
uptake of 3NBDC was time-dependent with around 80% of HeLa cells labelled with 3NBDC after 
7 hours incubation. The data is based on three independent experiments and is expressed as mean 
±SEM. B) A representative flow plot of 3NBDC stained HeLa cells after five hours incubation. C-
F) 3NBDC stained HeLa cell (purple) live images were taken by confocal microscopy at different 
time points. Scale bar = 30µm. 
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Additional studies were carried out on PMA differentiated THP-1 cells and HMDMs. Live cell 
images were taken by confocal microscopy. Figure 5.4 shows that THP-1 derived macrophages 
were labelled by 3NBDC after one hour incubation (Figure 5.4B) while HMDMs were labelled 
following overnight incubation. It should be noted that studies on the metabolic transformation of 
3NBDC by both THP1 cells and HMDMs have been carried out at time points up to 48 hours, and 
no significant metabolism of transformation of the 3NBDC has been observed. Taken together 
these results suggest that 3NBDC can readily label a variety of different cell types. 
 
 
      
Figure 5.4 THP-1 cell derived macrophages and human primary monocyte derived 
macrophages uptake of 3-NBD-Cholesterol. A) THP-1 cell derived macrophages (THP-1) were 
labelled with 3-NBD-Cholesterol (3NBDC) and images were taken by confocal microscope (a is 
control, b is stained). n=3. B) Human primary monocyte derived macrophages (HMDMs) were 
labelled with 3NBDC and images were taken by confocal microscope (c is control, d is stained). 
n=1. Scale bar = 30 µm.  
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5.3.3 Treating THP-1 derived macrophages with labelled extracellular vesicles  
To further explore the 3NBDC application, EVs were isolated from platelet concentrates and 
labelled with 3NBDC.  EV surface markers were characterised by flow cytometry and, as expected, 
were derived from platelets (Figure 5.5A). Isolated EVs were labelled with 3NBDC for 48 hours 
and analysed by flow cytometry. Following washing of the cells, approximately 40% of EVs were 
labelled with 3NBDC (Figure 5.5B). Co-incubation of THP-1 cell derived macrophages and 
3NBDC labelled EVs revealed a time-dependent increase in cellular fluorescence, with an 
observed plateau at approximately 16 hours (Figure 5.5C). As noted above, there are a number of 
mechanisms for the uptake of the 3NBDC labelled EVs - i) direct exchange between EVs 
membranes and cellular plasma membranes, ii) exchange between EVs and lipoproteins present in 
the medium followed by uptake of labelled lipoproteins by receptor mediated processes and iii) 
uptake of labelled EVs by phagocytosis. To estimate the magnitude of phagocytic versus other 
forms of uptake, parallel experiments with a non-phagocytic cell line (HEK-293T cells) were 
completed. Based on these experiments, HEK293T cell labelling was approximately 40% of that 
of the THP-1 cell derived macrophages, indicating that non-phagocytic processes account for 
about 40% of the labelling following incubation with 3NBDC labelled EVs. Taken together these 
results suggest that 3NBDC is a promising marker to label and track EVs in cell systems. 
 
Figure 5.5 THP-1 derived macrophage uptake f 3-NBD-Cholesterol labelled extracellular 
vesicles. A) A representative flow plot showing CD42b+ EVs (100% positive) derived from platelet 
concentrate. B) A representative flow plot showing around 40% EVs express 3-NBD-Cholesterol 
(NBD) after 48 hours incubation. C) THP-1 derived macrophages uptake of 3-NBD-Cholesterol 
labelled EVs was time-dependent. The data is based on five independent experiments and is 
expressed as mean ±SEM. 
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5.4 Discussion 
     Fluorescent cholesterol analogs, can closely mimic the properties of natural cholesterol and 
permit detection by microscopic techniques, therefore, a series of cholesterol probes with NBD 
fluorescence analogs have been widely studied to investigate the intracellular distribution and 
membrane organisation of cholesterol (110). These fluorescence cholesterol analogs have also 
demonstrated their potential as replacements for traditional radioisotope-labelled cholesterol for 
investigating lipids trafficking such as cholesterol efflux (248). Cholesterol efflux plays a key step 
in reverse cholesterol transport to remove excess cholesterol from the cell membrane (248). 
Previous studies have investigated HDL-mediated cholesterol efflux by applying 22NBDC (249, 
250). Other reports have also examined their ability to mimic the behaviour of natural cholesterol 
in the cell membrane by studying 22NBDC or 25NBDC (108, 109). However, there are no studies 
which have reported on the application of 3NBDC. Furthermore, reports have shown the half- time 
of transfer between liposomes or cells membranes by 22NBDC or 25NBDC is much faster than 
the half-time of transfer between liposomes or cell membranes for natural cholesterol (110, 111). 
It is worth nothing that the majority of biophysical studies have shown 22NBDC or 25NBDC as 
poor mimics of cholesterol in biological membranes (110). In this study, we tested the exchange 
time between the red cell membrane and plasma by 3NBDC labelling. The results have shown it 
takes around 7 hours to reach a plateau, which is consistent with the data obtained by radioisotope-
labelled cholesterol methods (245, 246). In addition, different cell lines are easily labelled with 
3NBDC and labelling may be readily observed by confocal microscopy and flow cytometry. In 
our studies, 3NBDC does not have the problem of photobleaching, which is a good advantage for 
dynamic measurements of cholesterol transport.  
EVs are lipid bilayer-enclosed vesicles released by cells. Currently, one of the main 
obstacles in the field of EVs is to develop a strategy to label all EVs instead of a subpopulation of 
EVs. Furthermore, EV tracking plays an important role in understanding the molecular biology, as 
well as therapeutic potential of EVs. There are some organic fluorescent dyes used for EV labelling 
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such as PKH dyes, however, it has been reported that these days have an in vivo half life ranging 
from 5 to >100 days (251), which may mislead the in vivo distribution of EVs. Furthermore, 
aggregation and micelle formation of lipophilic dyes may yield false signal of EVs (251). 
Therefore, new fluorescent dyes need to be developed to enable accurate, long-term imaging of 
EVs. In the present study, our data shows that 3NBDC labelled EVs are readily taken up by both 
phagocytic and non-phagocytic models. Although, the precise mechanism of uptake of EVs is not 
clear, a literature review suggested that cells take up EVs by several endocytic pathways, such as 
phagocytosis, lipid raft-mediated internalisation, caveolin-mediated and micropinocytosis uptake 
(252, 253). Our data of EV uptake, although limited to two cell lines, indicate that phagocytic 
processes are responsible for at least 60% of the uptake of labelled EVs. Further investigation to 
compare different NBD fluorescent analogs with traditional radioisotope-labelled methods such as 
[3H]-cholesterol may assist in determining the potential of 3NBDC as a cholesterol tracer.  
In conclusion, the results of this study indicate that 3NBDC has the potential to be used as 
a cholesterol biosensor in multiple applications. 
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6.0 General Discussion and Future work 
MPs are small vesicles released from the plasma membrane under normal physiological conditions. 
MPs contain active bio-lipids (such as cholesterol). Increased MPs levels and lipid abnormalities 
are observed among patients of autoimmune diseases (such as SLE and RA), however, no previous 
study has measured cholesterol levels derived from circulating MPs in healthy people and 
autoimmune diseases patients. To address this deficit, this thesis developed a method to measure 
MPC in circulating plasma. Furthermore, the reference value of MPC from a representative healthy 
population was established and we also demonstrated that MPC is a promising novel marker in 
autoimmune disorders. In addition, a novel cholesterol sensor (3NBDC) was studied in multiple 
applications. 
We demonstrated that MPs, with a significantly reduced lipoprotein amount can be 
effectively purified from human PFS of platelet concentrates and human plasma by the 
combination of centrifugation and SEC methods. The centrifugation method enables the      
removal of platelets which avoids MP activation by platelets. SEC is the most widely used method 
for MP isolation. Compared to classical time-consuming differential centrifugation, there is also 
reduced risk of protein aggregation or huge lipoprotein co-isolation, which often hampers the study 
of biological functions of MPs. In addition, differential centrifugation often results in low recovery 
of MPs due to the high viscosity of plasma (59). Other methods including precipitation and density 
gradient ultracentrifugation possess different drawbacks as mentioned in the introduction chapter. 
Recently, microfluidic devices have been added to the list of methods used for EV isolation, 
however, this application is limited due to the low yield EVs often obtained (59). 
The principle of SEC is separation based on a difference in size. The main advantage of 
SEC is that it can separate large and small molecules. As mentioned previously, the fact that 
cholesterol-carried lipoprotein size (HDL, LDL, IDL, VLDL) is around 5-80nm and MPs range in 
size from 100-1000nm enables MPs with reduced lipoprotein content to be isolated using SEC. 
Also, the SEC method only needs a small amount of plasma, which is feasible from a clinical 
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application point of view. The combination of centrifugation and SEC is therefore the most feasible 
method to study cholesterol contents of MPs. 
Based on robust and reproducible method development, we established a reference value 
for MPC in a healthy representative population. Furthermore we demonstrated that MPC is a novel 
biomarker in autoimmune diseases. Several studies have reported MPs contain cholesterol (24, 29, 
217), however, there is no study to date which has measured the level of MPC in circulating plasma. 
A number of studies report that MPs derived from platelet and endothelial cells hold diagnostic 
value in autoimmune disorders (166, 229, 230). Our results are consistent with previous studies, 
however, MPs derived from platelets or endothelial cells cannot classify different autoimmune 
disorders (such as SLE and RA) due to similar clinical symptoms. Instead, our results demonstrate 
that MPC is able to distinguish SLE from RA. One possible mechanism is that the serum 
cholesterol efflux capacity is impaired in autoimmune disorders which leads to cholesterol 
enrichment within the cell membrane, therefore, an increase in MPC is observed. A study has 
reported that microvesicles shed from the cell membrane can help cells to efflux cholesterol (218). 
Microvesicles were shown to be released from a monocyte cell line and primary human 
macrophages when cell membranes area enrich with cholesterol (254). The study has demonstrated 
overexpression of the cholesterol transporter ABCA1 contributes to cholesterol-rich EV release 
from human THP-1 macrophages, BHK and HepG2 cells (254).  In our study, it is noticeable that 
MPC is not increased in SLE patients. The possible reason is related to disease  status as most SLE 
patients were inactive which makes it challenging to find a difference from a diagnostic point of 
view.  In addition, our preliminary data suggests that MPs, derived from SLE or RA patients, play 
an anti-inflammatory role by reducing TLR4 and TNFα expression. Although a number of studies 
have reported MPs derived from autoimmune diseases have pro-inflammatory effects, increasing 
evidence suggests they also contain anti-inflammatory properties (234, 235). Studies report the 
protective effects of MPs derived from leucocytes, which carry an endogenous anti-inflammatory 
protein (Annexin 1) and release the anti-inflammatory cytokine transforming growth factor β1, 
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which also inhibits TNFα (255). However, certain methodologic differences including MPs 
isolation methods and timing of cell stimulation may lead to different results. 
In addition, we demonstrate 3NBDC is a versatile membrane cholesterol sensor. 
Cholesterol plays a key role in maintaining the biophysical properties of the cell membrane and 
the amount of membrane cholesterol is tightly controlled by lipid metabolism. Although, the 
intracellular transport of cholesterol is widely studied, the mechanisms regulating this transport 
are not fully understood. The NBD-group is linked to two main positions on the cholesterol 
backbone: 1). The NBD group is esterified to the hydroxyl group of cholesterol; 2). NBD group is 
covalently attached to the branched alkyl chain of cholesterol (241). Valid fluorescent analogs of 
cholesterol should closely mimic cholesterol. The chemical structure of 3NBDC allows the 
cholesterol to properly orient in the membrane bilayers, with the fluorescence tag outside the 
membrane. In addition, 3NBDC preferentially localises in the cell membrane, which has led to an 
application in monitoring membrane cholesterol. As is widely published, one of the main obstacles 
in the field of MPs is the development of a strategy to label all of the MPs instead of subpopulations 
of MPs. MPs released from the cell membrane contain cholesterol, which makes 3NBDC an 
attractive candidate to detect and track MPs.  
In summary, this is the first report on the reference value of MPs cholesterol in healthy 
people, and investigation into the use of MPC as a novel biomarker to diagnose and classify SLE 
and RA.  Furthermore, the work on 3NBDC applications lays the groundwork for future research 
on tracking both cell membrane cholesterol and EVs. 
 
Study limitation and Future direction 
A major limitation of this work was the number of patients and their disease status. The results 
should be considered only as preliminary because the number of patients was relatively small, 
therefore studies covering larger number of patients are needed to confirm these results. Regarding 
diseases status, only two SLE patients were active. This limited the assessment of the utility of 
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MPC to distinguish between SLE and healthy people. Another limitation was the cost of sepharose 
-CL2B. In our study, each sepharose column was used only for one donor to avoid cross-
contamination and lipoprotein contamination, which added to the cost of testing each sample 
considerably. For the 3NBDC study, there are two main limitations. One is that only three cell 
models (Erythrocytes, THP-1 derived macrophages and HEK293T cells) were studied. In order to 
fully confirm these findings, more cell models need to be explored. Another limitation is that these 
3NDBC data would need to be compared to the action of other NBD labelled fluorescence analogs 
in our hands, in order to make a truly informed comparison with 3NBDC.   
Future work should focus on the validation of the diagnostic value of MPC in RA patients. 
The validation method would need to involve a larger group of RA patients from multiple sites. It 
would be interesting to include RA patients with cardiovascular diseases in order to establish if 
MPC may be a potential biomarker in this regard. In addition, MPC needs to be investigated as a 
potential biomarker in other autoimmune disorders (eg. pSS) and other non-autoimmune diseases 
(eg. cancer). A considerable amount of work is needed to unravel the precise mechanisms of action 
of MPs on inflammatory responses in autoimmune. Ultimately a RA mouse model is needed to 
explore the immunomodulatory effects of MPs in vivo and fully identify new therapeutic targets.  
It would be valuable to combine 3NBDC labelling and different cells marker staining to identify 
the amount of MPC in various cells types using flow cytometry. This could be useful in diagnosing 
diseases by comparing the amounts of MPC from different cells in different diseases, but this also 
needs to be confirmed in a larger population. Tracking MPC with 3NBDC will help to elucidate 
the mechanisms of MPs uptake and metabolism in various cell and animal models. Additionally, 
comparison studies need to be applied to compare the application of 3NBDC and other cholesterol 
sensors (like radioactive cholesterol) to track cell membrane cholesterol.  
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Appendix I: List of awards, presentations, publication and modules 
Awards 
• Early Career Investigator Travel Stipend Awards for Kern Lipid Conference 2018, USA 
• 68th Lindau Nobel Laureate meeting award, 2018 (selected from over 20,000 students) 
• Student Travel Award for attendance at CYTO, 2018, Prague 
Presentations 
• International Conference on Euro Oncology, Breast Cancer & Biomarkers 2018” Studies 
on extracellular vesicle cholesterol in systemic lupus erythematosus Poster presentation 
(October, 2018, Netherlands) 
• Irish Society for Immunology Annual Meeting 2018,” Cholesterol containing 
microparticles accentuates MYD88 dependent pathways in autoimmune diseases.” Poster 
presentation (August, 2018, Dublin) 
• Kern Lipid Conference 2018,” Studies on Extracellular Vesicles Cholesterol in Systemic 
Lupus Erythematosus.” Poster presentation (August, 2018, US) 
• 64th Annual Scientific and Standardization Committee Meeting of the International 
Society on Thrombosis and Homeostasis”, Circulating cholesterol containing platelet-
derived microparticles contribute to the procoagulant state observed in Systemic Lupus 
Erythematosus.” Poster presentation (July, 2018, Dublin) 
• 68th Lindau Nobel Laureate Meeting Germany, selected from over 20,000 applicants 
globally to attend this meeting which will include 43 Nobel Laureate presentations and a 
trip to the Max Planck Institute. Poster presentation and Master Class attendance, (June, 
2018, Germany) 
• 33rd Congress of the International Society for Advancement of Cytometry,” Novel 
Application of 3-Hexanoyl-NBD Cholesterol (3NBDC) as a Biomedical Tool to Detect 
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Membrane Cholesterol by Flow Cytometry ", Poster presentation (April, 2018, Czech 
Republic) 
• ISEV Workshop "Membranes and EVs” Development of 3-Hexanoyl- NBD Cholesterol 
(3NBDC) as a biochemical tool to detect cholesterol in microparticle membranes”, Oral 
presentation (March, 2018, USA) 
• DIT 7th Annual Graduate Research Symposium,” Circulating microparticles are a novel 
carrier of cholesterol in the blood stream”, Poster presentation, (Feb, 2017, DIT, Ireland) 
• Annual Meeting of the Cytometry Society of Ireland. “Application of novel 3-NBD-
cholesterol in cell biology”, Poster presentation (Nov, 2016, Ireland) 
• 4th Helmholtz-Nature Medicine Diabetes conference, “Decreasing CD51+EMP in 
diabetes patients with hypertension”, Oral presentation at the Scientific Round Table 
Session (Sept, 2016, Germany) 
Publications 
• Shuaishuai Hu, Claire Wynne, Steve Meaney. (2018) Studies on extracellular vesicle 
cholesterol in systemic lupus erythematosus (Abstract accepted in Conference 
proceeding) Journal of Cancer Science and Therapy (10) DOI: 10.4172/1948-5956-C12-
157 
• Ashley E. Russell , Alexandra Sneider, Paolo Bergese, Suvendra Bhattacharyya, 
Alexander Cocks, Emanuele Cocucci, Uta Erdbruegger, Juan M. Falcon-Perez, David 
Freeman, Thomas M. Gallagher, Shuaishuai Hu, Yiyao Huang, Steven M. Jay et al. 
Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: An ISEV 
Position Paper arising from the ISEV Membranes and EVs Workshop. Journal of 
Extracellular Vesicles (Accepted). 
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Modules 
Discipline skills training: 20 Credits 
● Animal cell culture and proteomic technology (5 credits)  
● Diagnostic Immunology and Transplantation (5 credits)  
● Metabolic and Endocrine Disorder (5 credits)  
● Cell Biology and Immunology (5 credits) 
Employability skills training: 20 Credits 
• Introduction to Pedagogy (5 credits) 
• Writing in Science and Engineering (6 credits) 
• Research Methods and Biostatistics (10 credits) 
 
 
      
 
 
 
 
      
      
 
